WO2009043784A1 - Cyclopropyl aryl amide derivatives and uses thereof - Google Patents

Cyclopropyl aryl amide derivatives and uses thereof Download PDF

Info

Publication number
WO2009043784A1
WO2009043784A1 PCT/EP2008/062813 EP2008062813W WO2009043784A1 WO 2009043784 A1 WO2009043784 A1 WO 2009043784A1 EP 2008062813 W EP2008062813 W EP 2008062813W WO 2009043784 A1 WO2009043784 A1 WO 2009043784A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
cyclopropyl
benzamide
dimethyl
methoxy
Prior art date
Application number
PCT/EP2008/062813
Other languages
French (fr)
Inventor
Daisy Joe Du Bois
David Nigel Hurst
David Garrett Loughhead
Hans Maag
Jason Manka
David Bernard Smith
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to KR1020107007299A priority Critical patent/KR101178674B1/en
Priority to JP2010527409A priority patent/JP5362729B2/en
Priority to CN2008801100940A priority patent/CN101815512B/en
Priority to ES08804712.1T priority patent/ES2460897T3/en
Priority to EP08804712.1A priority patent/EP2207540B1/en
Priority to MX2010003155A priority patent/MX2010003155A/en
Priority to CA2699625A priority patent/CA2699625C/en
Priority to AU2008307195A priority patent/AU2008307195B2/en
Publication of WO2009043784A1 publication Critical patent/WO2009043784A1/en
Priority to IL204437A priority patent/IL204437A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/62—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

  • This invention relates to nicotinic acetylcholine receptor ligands (nAChR), and particularly to positive allosteric modulators for the ⁇ 7 nAChR subtype, and methods of making and using such compounds.
  • nAChR nicotinic acetylcholine receptor ligands
  • One aspect of the invention provides compounds of formula I:
  • Ar 1 and Ar 2 each independently is: optionally substituted aryl; or optionally substituted heteroaryl; and
  • R 1 and R 2 each independently is: hydrogen; fluoro; Ci_ 6 alkyl; or halo-Ci_ 6 alkyl.
  • the invention also provides pharmaceutical compositions and methods of using the aforementioned compounds as well as methods to synthesize above compounds.
  • Nicotinic acetylcholine receptors are members of the ligand-gated ion channel family. When activated, the conductance of ions across the nicotinic ion channels increases. Nicotinic alpha 7 receptor (alpha 7 nAChR) forms a homopentameric channel in vitro that is highly permeable to calcium cations. Each alpha 7 nAChR has four transmembrane domains, known as Ml, M2, M3, and M4. The M2 domain has been suggested to form the wall lining the channel. Sequence alignment shows that the alpha 7 nAChR is highly conserved during evolution. The M2 domain that lines the channel is identical in protein sequence from chick to human.
  • Alpha 7 nAChR is described by, Revah et al. (1991), Nature, 353, 846-849; Galzi et al. (1992), Nature 359, 500-505; Fucile et al. (2000), PNAS 97(7), 3643-3648; Briggs et al. (1999), Eur. J. Pharmacol 366 (2-3), 301-308; and Gopalakrishnan et al. (1995), Eur. J. Pharmacol. 290(3), 237- 246.
  • alpha 7 nAChR channel is expressed in various brain regions and is believed to be involved in many important biological processes in the central nervous system (CNS), including learning, memory and attention (Levin et al., Psychopharmacology (1998), 138, 217-230).
  • Alpha 7 nAChR are localized on both presynaptic and postsynaptic terminals and have been suggested to be involved in modulating synaptic transmission.
  • Agonists of alpha 7 nAChR have been shown to improve attention and cognition in Alzheimer's and attention deficit disorder conditions (Wilens et al., Am. J. Psychiatry (1999), 156(12), 1931-1937).
  • alpha 7 nAChR receptor has been shown to modulate production of pro-inflammatory cytokines, including interleukins (ILs), tumor necrosis factor (TNF) alpha, and high-mobility group box (HMGB-I), and to inhibit inflammatory signalling in the CNS (de Jonge et al., Br. J. Pharmacol. (2007), 1-15).
  • ILs interleukins
  • TNF tumor necrosis factor
  • HMGB-I high-mobility group box
  • the alpha 7 nAChR receptor has a role in modulating CNS pain transmission, and alpha 7 nAChR agonists have shown an antinociceptive effect in an acute pain model (Damaj et al., Neuropharmacol. (2000) 39, 2785-2791.
  • acetylcholine is an endogenous agonist of alpha 7 nAChR
  • agonists that act at the same site as ACh can stimulate and possibly block receptor activity through desensitization and competitive blockade processes (Forman et al., BiophysicalJ. (1988), 54(1), 149-158) and lead to prolonged receptor inactivation (Buisson et al., J. Neurosci. (2001), 21(6), 1819-1829).
  • Desensitization limits the duration that the ion channel remains activated during agonist application.
  • the enhancement of Alpha 7 nAChR activity provided by such agonists will also increase competition with ACh, and therefore limit the usefulness of agonists as drugs.
  • Positive allosteric modulators of the nicotinic alpha 7 receptor channel enhance the activity of ACh and other nicotinic alpha 7 receptor agonists. Positive allosteric modulators activate alpha 7 nAChR when sufficient ACh is present in the central nervous system. Positive allosteric modulators of alpha 7 nAChRs thus are useful for treatment of CNS, pain and inflammatory diseases or conditions, to regulate CNS functions such as cognition, learning, mood, emotion and attention, and control production of pro- inflammatory cytokines associated with pain and inflammatory conditions. There is accordingly a need for new positive allosteric modulators of the the nicotinic alpha 7 receptor channel.
  • Antagonist refers to a compound that enhances the activity of another compound or receptor site.
  • Alkyl means the monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having from one to twelve carbon atoms.
  • “Lower alkyl” refers to an alkyl group of one to six carbon atoms, i.e. Ci-C ⁇ alkyl.
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl, hexyl, octyl, dodecyl, and the like.
  • branched alkyl are isopropyl, isobutyl, tert-butyl, and the like.
  • Preferred alkyl is lower alkyl as defined herein.
  • Alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g., methylene, ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butylene, pentylene, and the like.
  • Alkoxy means a moiety of the formula -OR, wherein R is an alkyl moiety as defined herein. Examples of alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, tert-butoxy and the like.
  • Alkoxyalkyl means a moiety of the formula -R'-R", where R' is alkylene and R" is alkoxy as defined herein.
  • alkoxyalkyl groups include, by way of example, 2- methoxyethyl, 3-methoxypropyl, l-methyl-2-methoxyethyl, l-(2-methoxyethyl)-3- methoxypropyl, and l-(2-methoxyethyl)-3-methoxypropyl.
  • Alkylcarbonyl means a moiety of the formula -C(O)-R, where R is alkyl as defined herein.
  • Alkylsulfonyl means a moiety of the formula -SO 2 -R' where R' is alkyl as defined herein.
  • Amino means a moiety of the formula -NRR' where R and R' each independently is hydrogen or alkyl as defined herein.
  • Amino sulfonyl means a moiety of the formula -SO 2 -R' where R' is amino as defined herein.
  • Alkylsulfonylalkyl means a moiety of the formula -R b -SO 2 -R a , where R a is alkyl and R b is alkylene as defined herein.
  • exemplary alkylsulfonylalkyl groups include, by way of example, 3-methanesulfonylpropyl, 2-methanesulfonylethyl, 2-methanesulfonylpropy, and the like.
  • Alkylsulfonyloxy means a moiety of the formula R a -SO 2 -O-, where R a is alkyl as defined herein.
  • Antagonist refers to a compound that diminishes or prevents the action of another compound or receptor site.
  • Aryl means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring.
  • the aryl group can be optionally substituted as defined herein.
  • aryl moieties include, but are not limited to, phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl, methylenedioxy
  • a preferred aryl is optionally substituted phenyl.
  • Aryloxy means a moiety of the formula -OR, wherein R is an aryl moiety as defined herein.
  • Alkoxy means a moiety of the formula -OR, wherein R is an aralkyl moiety as defined herein.
  • Cyanoalkyl means a moiety of the formula -R'-R", where R' is alkylene as defined herein and R" is cyano or nitrile.
  • Cycloalkyl means a monovalent saturated carbocyclic moiety consisting of mono- or bicyclic rings. Cycloalkyl can optionally be substituted with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unless otherwise specifically indicated. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, including partially unsaturated derivatives thereof.
  • Exemplary cycloalkyloxy include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like.
  • Cycloalkylalkyl means a moiety of the formula -R'-R", where R' is alkylene and R" is cycloalkyl as defined herein.
  • Cycloalkylalkyloxy and "cycloalkylalkoxy”, which may be used interchangeably, mean a group of the formula -OR wherein R is cycloalkylalkyl as defined herein.
  • Exemplary cycloalkyloxy include cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy and the like.
  • Heteroalkyl means an alkyl radical as defined herein, including a branched C 4 -Cy-alkyl, wherein one, two or three hydrogen atoms have been replaced with a substituent independently selected from the group consisting of -OR a , -NR b R c , and -S(O) n R d (where n is an integer from 0 to 2), with the understanding that the point of attachment of the heteroalkyl radical is through a carbon atom, wherein R a is hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; R b and R c are independently of each other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; and when n is 0, R d is hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl, and when n is 1 or 2, R d is alkyl, cyclo
  • Representative examples include, but are not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxy-l -hydro xymethylethyl, 2,3- dihydroxypropyl, 1 -hydro xymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 2- hydroxy-1-methylpropyl, 2-aminoethyl, 3-aminopropyl, 2-methylsulfonylethyl, aminosulfonylmethyl, aminosulfonylethyl, amino sulfonylpropyl, methylaminosulfonylmethyl, methylaminosulfonylethyl, methylaminosulfonylpropyl, and the like.
  • heteroalkyl are hydroxyalkyl, alkylhydroxyalkyl, aminoalkyl, mono alky lamino alkyl, and dialkylamino alkyl.
  • Heteroaryl means a monocyclic, bicyclic or tricyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring.
  • the heteroaryl ring may be optionally substituted as defined herein.
  • heteroaryl moieties include, but are not limited to, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, thienyl, thiophenyl, furanyl, pyranyl, pyridinyl, pyrrolyl, pyrazolyl, pyrimidyl, quinolinyl, isoquinolinyl, benzofuryl, benzo furanyl, benzo thiophenyl, benzothiopyranyl, benzimidazolyl, benzo xazo IyI, benzooxadiazolyl, benzo thiazolyl, benzo thiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl, quinoxalinyl, purinyl, quinazolinyl,
  • Preferred heteroaryl include indolyl, pyridinyl, pyrimidinyl, thienyl, furanyl pyrrolyl, isoxazolyl, imidazolyl and pyrazolyl, each of which may be optionally substituted.
  • halo and “halogen”, which may be used interchangeably, refer to a substituent fluoro, chloro, bromo, or iodo.
  • Haloalkyl means alkyl as defined herein in which one or more hydrogen has been replaced with same or different halogen.
  • Exemplary haloalkyls include -CH 2 Cl, -CH 2 CF 3 , -CH 2 CCl 3 , perfiuoroalkyl (e.g., -CF 3 ), and the like.
  • Haloalkoxy means a moiety of the formula -OR, wherein R is a haloalkyl moiety as defined herein.
  • haloalkoxy moieties include, but are not limited to, trifluoromethoxy, difluoromethoxy, 2,2,2-trifluoroethoxy, and the like.
  • Hydro xyalkyl refers to a subset of heteroalkyl and refers in particular to an alkyl moiety as defined herein that is substituted with one or more, preferably one, two or three hydroxy groups, provided that the same carbon atom does not carry more than one hydroxy group.
  • Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1 -(hydro xymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 2-hydroxy-l- hydroxymethylethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)- 3-hydroxypropyl.
  • Heterocycloamino means a saturated ring wherein at least one ring atom is N, NH or
  • N-alkyl and the remaining ring atoms form an alkylene group.
  • Heterocyclyl means a monovalent saturated moiety, consisting of one to three rings, incorporating one, two, or three or four heteroatoms (chosen from nitrogen, oxygen or sulfur).
  • the heterocyclyl ring may be optionally substituted as defined herein.
  • heterocyclyl moieties include, but are not limited to, optionally substituted piperidinyl, piperazinyl, homopiperazinyl, azepinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyridinyl, pyridazinyl, pyrimidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinuclidinyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazolylidinyl, benzo thiazolidinyl, benzoazolylidinyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinylsulfoxide,
  • Optionally substituted when used in association with "aryl", phenyl", “heteroaryl” (including indolyl such as indol-1-yl, indol-2-yl and indol-3-yl, 2,3-dihydroindolyl such as 2,3-dihydroindol-l-yl, 2,3-dihydroindol-2-yl and 2,3-dihydroindol-3-yl, indazolyl such as indazol-1-yl, indazol-2-yl and indazol-3-yl, benzimidazolyl such as benzimidazol-1-yl and benzimidazol-2-yl, benzo furanyl such as benzo furan-2-yl and benzo furan-3-yl, benzo thiophenyl such as benzo thiophen-2-yl and benzo thiophen-3-yl, benzoxazol-2
  • aryl phenyl
  • heteroaryl cycloalkyl
  • heterocyclyl include alkyl, halo, haloalkyl, alkoxy, cyano, amino (i.e. -NH 2 , -NH(alkyl), -N(alkyl) 2 ), aminosulfonyl (i.e. -SO 2 NH 2 , -SO 2 NH(alkyl),
  • alkylsulfonyl and phenyl optionally substituted by 1, 2 or 3 alkoxy, alkyl or halo (preferably by alkoxy). More preferred substituents are methyl, tert-butyl, fluoro, chloro, bromo, trifluoromethyl, methoxy, cyano, aminosulfonyl (i.e. sulfamoyl), methylaminosulfonyl (i.e. methylsulfamoyl), dimethylaminosulfonyl (i.e. dimethylsulfamoyl), methanesulfonyl and methoxyphenyl. More preferred substituents are methyl, fluoro, chloro, trifluoromethyl, methoxy, amino, aminosulfonyl and methanesulfonyl.
  • Module means a molecule that interacts with a target. The interactions include, but are not limited to, agonist, antagonist, and the like, as defined herein.
  • Disease and Disease state means any disease, condition, symptom, disorder or indication.
  • Inert organic solvent or “inert solvent” means the solvent is inert under the conditions of the reaction being described in conjunction therewith, including for example, benzene, toluene, acetonitrile, tetrahydrofuran, N,N-dimethylformamide, chloroform, methylene chloride or dichloromethane, dichloroethane, diethyl ether, ethyl acetate, acetone, methyl ethyl ketone, methanol, ethanol, propanol, isopropanol, tert-butanol, dioxane, pyridine, and the like.
  • the solvents used in the reactions of the present invention are inert solvents.
  • “Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” of a compound means salts that are pharmaceutically acceptable, as defined herein, and that possess the desired pharmacological activity of the parent compound.
  • Such salts include: acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydro xynaphtoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, p- toluenesulfonic acid, trimethylacetic acid, and the like; or salts formed when an acidic proton present in the parent compound either is
  • Acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, and the like.
  • Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.
  • the preferred pharmaceutically acceptable salts are the salts formed from acetic acid, hydrochloric acid, sulphuric acid, methanesulfonic acid, maleic acid, phosphoric acid, tartaric acid, citric acid, sodium, potassium, calcium, zinc, and magnesium. It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same acid addition salt.
  • Solidvates means solvent additions forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as H 2 O, such combination being able to form one or more hydrate. "Subject” means mammals and non-mammals.
  • Mammals means any member of the mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like.
  • the term "subject” does not denote a particular age or sex.
  • Pain and pain conditions as used herein means pain associated with any of a wide variety of causes, including but not limited to, inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injuries (including fractures and sports injuries), and pain associated with functional bowel disorders such as irritable bowel syndrome.
  • Inflammation means any pathological process characterized by injury or destruction of tissues resulting from cytologic reactions, chemical reactions or other causes.
  • Inflammation may be manifested by signs of pain, heat, redness, swelling, and loss of function.
  • Inflammation indications include, but are not limited to, bacterial, fungal or viral infections, rheumatoid arthritis, osteoarthritis, surgery, bladder infection or idiopathic bladder inflammation, over-use, old age, or nutritional deficiencies, prostatis and conjunctivitis.
  • Cognition means any mental process associated with acquiring and retaining knowledge.
  • a “cognition disorder” means any disturbance to the mental process or processes related to thinking, reasoning, judgment ad memory. Cognition disorders may result from or other wise be associated with Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychosis, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, sleep disorders, feeding disorders such as anorexia, bulimia, and obesity, panic attacks, akathisia, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • ADHD attention deficit hyperactivity disorder
  • ADD attention deficit disorder
  • “Therapeutically effective amount” means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state.
  • the “therapeutically effective amount” will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
  • Treating" or “treatment” of a disease state includes:
  • treating when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
  • Nomenclature and Structures In general, the nomenclature used in this Application is based on AUTONOMTM v.4.0, a Beilstein Institute computerized system for the generation of IUPAC systematic nomenclature. Chemical structures shown herein were prepared using ISIS ® version 2.2.
  • Ar 1 and Ar 2 each independently is: optionally substituted aryl; or optionally substituted heteroaryl; and R 1 and R 2 each independently is: hydrogen; fluoro; Ci_ 6 alkyl; or halo-Ci_ 6 alkyl.
  • the compounds of the invention may be of formula Ia or Ib:
  • Ar 1 , Ar 2 , R 1 and R 2 are as defined herein.
  • R 1 and R 2 are H or Ci_ 6 alkyl. In certain embodiments of formula I, Ia or Ib, R 1 and R 2 are Ci_ 6 alkyl. In certain embodiments of formula I, Ia or Ib, Ar 1 and Ar 2 are phenyl, indolyl, pyridinyl, pyrimidinyl, thienyl, furanyl pyrrolyl, isoxazolyl, imidazolyl or pyrazolyl, each optionally substituted as described herein.
  • Ar 1 and Ar 2 are phenyl, pyridinyl, or isoxazolyl, each optionally substituted as described herein.
  • Ar 1 is phenyl, indolyl, pyridinyl, pyrimidinyl, thienyl, furanyl pyrrolyl, isoxazolyl, imidazolyl or pyrazolyl, each optionally substituted as described herein; and Ar 2 is phenyl, optionally substituted as described herein
  • Ar 1 is phenyl, pyridinyl, or isoxazolyl, each optionally substituted as described herein; and Ar 2 is phenyl optionally substituted as described herein.
  • the optional substituents of Ar 1 and Ar 2 are independently selected from one, two or three groups of
  • Ci_ 6 alkyl Ci_ 6 alkyl; halo;
  • Ci_6alkyl-amino di-C i _6alkyl-amino ; nitro; or -(CR a R b ) m -X-R 3 wherein:
  • X is C(O) or S(O) n ; m is 0 or 1 ; n is 0, 1 or 2;
  • R a and R b each independently is: hydrogen; or Ci_ 6 alkyl; and R 3 is: hydrogen; Ci- 6 alkyl; Ci_ 6 alkoxy; hetero-Ci_ 6 alkyl; halo-Ci-ealkyl;
  • R 5 is: hydrogen; Ci_ 6 alkyl; hetero-Ci_ 6 alkyl;
  • the optional substituents of Ar 1 and Ar 2 are independently selected from one, two or three groups of: halo;
  • Ci_6alkyl-amino di-C i _ 6 alkyl-amino ; nitro; or
  • X is C(O) or S(O) 2 ;
  • R 3 is -NR 4 R 5 , and R 4 and R 5 each independently is: hydrogen; or Ci_ 6 alkyl.
  • the optional substituents of Ar 1 and Ar 2 are independently selected from one, two or three groups of alkyl, halo, haloalkyl, alkoxy, cyano, amino (i.e. -NH 2 , -NH(alkyl), -N(alkyl)2), aminosulfonyl (i.e. -SO 2 NH 2 , -
  • the optional substituents of Ar 1 and Ar 2 are independently selected from one, two or three groups of methyl, tert-butyl, fluoro, chloro, bromo, trifluoromethyl, methoxy, cyano, aminosulfonyl (i.e. sulfamoyl), methylaminosulfonyl (i.e. methylsulfamoyl), dimethylaminosulfonyl (i.e. dimethylsulfamoyl), methanesulfonyl and methoxyphenyl.
  • the optional substituents of Ar 1 are independently selected from one, two or three groups of methyl, tert-butyl, fluoro, chloro, trifluoromethyl, methoxy, aminosulfonyl (i.e. sulfamoyl), methanesulfonyl or methoxyphenyl.
  • the optional substituents of Ar 2 are independently selected from one, two or three groups of methyl, chloro, bromo, trifluoromethyl, methoxy, cyano, aminosulfonyl (i.e. sulfamoyl), methylaminosulfonyl (i.e. methylsulfamoyl), dimethylaminosulfonyl (i.e. dimethylsulfamoyl), or methanesulfonyl.
  • Ia or Ib, Ar 1 and Ar 2 are optionally substituted phenyl.
  • Ia or Ib, Ar 1 and Ar 2 are phenyl, each of which is optionally substituted with one, two or three groups each independently selected from:
  • Ci_6alkyl-amino di-Ci_6alkyl-amino; nitro; or
  • X is C(O) or S(O) n ;
  • m is 0 or 1 ;
  • n is 0, 1 or 2;
  • R a and R b each independently is: hydrogen; or Ci_ 6 alkyl; and R 3 is: hydrogen; Ci_ 6 alkyl; Ci_ 6 alkoxy; hetero-Ci_ 6 alkyl; halo-Ci-ealkyl;
  • R 5 is: hydrogen
  • hetero-Ci_ 6 alkyl C 3 - 7 cycloalkyl; aryl; heteroaryl; heterocyclyl; C 3 _ 7 cycloalkyl-Ci_ 6 alkyl; aryl-Ci_ 6 alkyl; heteroaryl-Ci_ 6 alkyl; or heterocyclyl-Ci- ⁇ alkyl.
  • Ia or Ib, Ar 1 and Ar 2 each are phenyl optionally substituted with one, two or three groups each independently selected from: Ci_ 6 alkyl; halo;
  • Ci_6alkyl-amino di-C i _6alkyl-amino ; nitro;
  • X is C(O) or S(O) n ; wherein n is 0, 1 or 2; R 3 is -NR 4 R 5 , and R 4 and R 5 each independently is: hydrogen; or Ci_ 6 alkyl.
  • Ar 1 is phenyl optionally substituted with one, two or three groups each selected independently from halo, halo-Ci_ 6 alkyl, Ci_ 6 alkyl and Ci_6alkoxy.
  • Ar 1 is phenyl optionally substituted with one, two or three groups each selected independently from halo and Ci_6alkoxy. In certain embodiments of formula I, Ia or Ib, Ar 1 is phenyl substituted one, two or three times with a group or groups independently selected from chloro, fluoro, methyl and methoxy.
  • Ar 1 is 5-chloro-2-methoxy-phenyl, 5- chloro-2,4-dimethoxy-phenyl, phenyl, 4-methoxy-phenyl, 4-methoxy-2-methyl-phenyl,
  • Ar 1 is 4-trifluoromethyl-phenyl, A- aminosulfonyl-phenyl, 4-N-methylamino-phenyl or 4-N,N-dimethylamino-phenyl. In certain embodiments of formula I, Ia or Ib, Ar 1 is phenyl substituted once or twice with methoxy and optionally substituted once with chloro.
  • Ar 1 is phenyl substituted one, two or three times with a group or groups independently selected from chloro and methoxy.
  • Ar 1 is 5-chloro-2-methoxy-phenyl, 5- chloro-2,4-dimethoxy-phenyl, phenyl, 4-methyl-phenyl, 2-methoxy-5-methyl-phenyl, 2- methyl-5-methoxy-phenyl, 4-methoxy-2-methyl-phenyl, 2,5-dimethoxy-phenyl, A- methoxy-phenyl, 4-chloro-phenyl, 3,4-dichloro-phenyl, 3-chloro-phenyl, 2-methoxy- phenyl, 4-tert-butyl-phenyl, 2,4-dimethoxy-phenyl, 3-trifluoromethyl-phenyl, A- methanesulfonyl-phenyl, 4-aminosulfonyl-phenyl, 4-trifluoromethyl-phenyl, 5-fluoro-2- methoxy-phenyl, 2-methoxy-5-trifluor
  • Ar 1 is optionally substituted heteroaryl.
  • Preferred heteroaryl include pyridinyl, pyrimidinyl, thienyl, furanyl, thiazolyl, oxazolyl, isothiazolyl and isoxaloyl, each of which may be optionally substituted with one or two groups each selected independently from halo, Ci_6alkyl and Ci_6alkoxy.
  • Ar 1 is pyridinyl or isoxaloyl, each of which may be optionally substituted with one or two groups each selected independently from halo, methyl and methoxy.
  • Ar 2 is phenyl optionally substituted once at the 4-position with halo, Ci_ 6 alkyl, cyano, halo-Ci_ 6 alkyl, Ci_ 6 alkoxy or -(CR a R b ) m -X-R 3 wherein: m is 0; X is -SO 2 -; R 3 is Ci- ⁇ alkyl or -NR 4 R 5 , and
  • R 4 and R 5 each independently is: hydrogen; or Ci_ 6 alkyl.
  • Ar 2 is phenyl substituted at the 4-position with cyano, -SO 2 -NR 5 R 6 , or -SO 2 -CH 3 .
  • Ar 2 is phenyl substituted at the 4-position with -SO 2 -NR 5 R 6 .
  • Ar 2 is phenyl substituted at the 4-position with -SO 2 NH 2 or -SO 2 -CH 3 .
  • Ar 2 is phenyl substituted at the 4-position with -SO 2 NH 2 .
  • Ar 2 is phenyl substituted at the 4-position with -SO 2 CH 3 .
  • Ar 2 is phenyl, 4-aminosulfonyl-phenyl, A- methylaminosulfonyl-phenyl, 4-dimethylaminosulfonyl-phenyl, 4-trifluoromethyl-phenyl,
  • R 1 and R 2 are Ci_ 6 alkyl. In certain embodiments of formula I, Ia or Ib, one of R 1 and R 2 is hydrogen and the other is Ci_ 6 alkyl.
  • one of R 1 and R 2 is hydrogen and the other is methyl or ethyl.
  • Ia or Ib, R 1 and R 2 are methyl. In certain embodiments of formula I, Ia or Ib, R 1 and R 2 are hydrogen.
  • the subject compounds are of formula II:
  • R 1 and R 2 are d_ 6 alkyl; and R 6 and R 7 each independently is: Ci_ 6 alkyl; halo;
  • Ci_ 6 alkyl-amino di-C i _ 6 alkyl-amino ; nitro;
  • R 3 is Ci- ⁇ alkyl or -NR 4 R 5 , and R 4 and R 5 each independently is: hydrogen; or Ci_ 6 alkyl.
  • R 1 and R 2 are methyl.
  • p is from 1 to 3 and each R 6 is independently:
  • Ci_6alkoxy halo-Ci_6alkoxy; or halo-Ci- ⁇ alkyl.
  • R 7 is C- ⁇ alkyl, halo- C-i- ⁇ alkyl or -(CR a R b ) m -X-R 3 wherein: m is 0; X is -SO 2 -; R 3 is Ci- ⁇ alkyl or -NR 4 R 5 , and
  • R 4 and R 5 each independently is: hydrogen; or Ci_ 6 alkyl.
  • p is from 1 to 3 and R 6 is halo or methoxy.
  • q is 1 and R 7 is -SO 2 NR 4 R 5 ,
  • R 1 and R 2 are methyl.
  • one of R 1 and R 2 is hydrogen and the other is methyl or ethyl.
  • R 1 and R 2 are hydrogen.
  • p is from 0 to 3 and each R 6 is independently: Ci_ 6 alkyl; halo;
  • R 4 and R 5 each independently is: hydrogen; or
  • Ci_ 6 alkyl In certain embodiments of formula II, Ha or lib, q is 1 and R 7 is:
  • Ci_6alkyl-amino di-Ci_6alkyl-amino; nitro;
  • R 4 and R 5 each independently is: hydrogen; or Ci_ 6 alkyl.
  • Ci_6alkoxy halo-Ci_6alkoxy; or halo-Ci- ⁇ alkyl.
  • p is from 1 to 3 and each R 6 is independently methyl, fluoro, chloro, methoxy or trifluoromethyl. In certain embodiments of formula II, Ha or lib, p is from 1 to 3 and each R 6 is independently chloro or methoxy.
  • R 7 is halo, cyano;, Ci_6alkyl, halo-Ci_ 6 alkyl Ci_ 6 alkoxy; or -(CR a R b ) m -X-R 3 wherein: m is 0; X is -SO 2 -; R 3 is Ci- ⁇ alkyl or -NR 4 R 5 , and R 4 and R 5 each independently is: hydrogen; or
  • Ci_ 6 alkyl Ci_ 6 alkyl
  • the subject compounds are of formula III:
  • each R 6 is independently selected from: Ci_ 6 alkyl; halo;
  • R 3 is Ci_ 6 alkyl or -NR 4 R 5 , and R 4 and R 5 each independently is: hydrogen; or Ci_ 6 alkyl.
  • p is from O to 3; each R 6 is independently selected from: halo;
  • R 4 and R 5 each independently is: hydrogen; or d-ealkyl.
  • R 3 is -SO 2 NR > 4 4Rr, 3 5.
  • R 4 is hydrogen or methyl.
  • the subject compounds may be of formula Ilia or IHb:
  • Ci_6alkyl-amino di-C i _ 6 alkyl-amino ; nitro;
  • X is -SO 2 -
  • R 3 is Ci- ⁇ alkyl or -NR 4 R 5 .
  • R 4 and R 5 each independently is: hydrogen; or
  • Ci_ 6 alkyl Ci_ 6 alkyl
  • Ci_6alkoxy halo-Ci_6alkoxy; or halo-Ci_ 6 alkyl.
  • Ilia or IHb, p is from 1 to 3 and each R 6 is independently methyl, fluoro, chloro, methoxy or trifluoromethyl.
  • R 7 is -(CR a R b ) m -X-R 3 wherein: m is 0; X is -SO 2 -;
  • R 3 is Ci- ⁇ alkyl or -NR 4 R 5 .
  • R 4 and R 5 each independently is: hydrogen; or Ci_ 6 alkyl.
  • R 7 is -SO 2 NR 5 R 6 .
  • R 7 is -SO 2 NH 2 .
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R a or R b herein are alkyl or contain an alkyl moiety, such alkyl is preferably lower alkyl, i.e. Ci-C ⁇ alkyl, and more preferably Ci- C 4 alkyl.
  • the following synthetic reaction schemes are merely illustrative of some methods by which the compounds of the present invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this Application.
  • the starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.
  • reaction described herein preferably are conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about -78 0 C to about 150 0 C, more preferably from about 0 0 C to about 125 0 C, and most preferably and conveniently at about room (or ambient) temperature, e.g., about 2O 0 C.
  • Scheme A illustrates one synthetic procedure usable to prepare compounds of the invention, wherein R is lower alkyl, X is hydroxy, halo or alkoxy, and Ar 1 , Ar 2 , R 1 , and R 2 are as defined herein.
  • aryl aldehyde compound a is reacted with cyano ester compound b to afford an arylonitrile ester compound c.
  • This reaction may be carried out in the presence of amine base catalyst.
  • Compound c is treated with nitro compound d step 2 to provide cyclopropyl nitrile ester compound e.
  • nitrile ester compound e is hydro lized under basic conditions to give cyclopropyl nitrile acid compound f.
  • compound f is heated in the presence of base to afford cyclopropyl nitrile compound g.
  • Nitrile compound g is then converted to cyclopropyl amide compound h in step 5 by treatment of compound g with hydrogen peroxide in the presence of base.
  • step 6 cyclopropyl amide compound is treated with bromine and NaOH or like base to afford cyclopropyl amine compound i.
  • Amine compound i then undergoes an amide coupling reaction with acid compound j in step 7 to yield compound k, which is a compound of formula I in accordance with the invention.
  • Numerous variations on the procedures of Scheme A are possible and will be readily apparent to those skilled in the art.
  • nitrile compound g may be hydro lized directly to a carboxylic acid compound in step 5, and then treated with ethyl chloro formate followed by azide to form compound i.
  • the amide formation of step 7 may utilize a carbodiimide such as dicyclohexylcarbodiimide, l-(3- dimethylaminopropyl)-3-ethylcarbodiimide methiodide or other diimide as used in conventional amide coupling reactions. Desired stereochemistry may be introduced by selection of appropriate starting materials and/or use of chiral separation techniques.
  • the amine compound i in many embodiments may undergo chromatographic chiral resolution to provide specific enantiomers.
  • Scheme B illustrates another synthetic procedure for the compounds of the invention, wherein R is lower alkyl (preferably methyl), X is hydroxy, halo or alkoxy, and Ar 1 , Ar 2 , R 1 , and R 2 are as defined herein.
  • step 1 of Scheme B amide compound m is treated with trifluoro acetic anhydride, followed by styryl compound n, to afford cyclobutanone compound o.
  • step 2 cyclobutanone o is treated with Lithium bis(trimethylsilyl)amide, followed by n-bromo- succinimide or like brominating agent, then acid, and then base, to afford cyclopropyl acid compound p.
  • Cyclopropyl compound p is converted to amine g in step 3 by treatment with chloro formate ester, followed by sodium azide and acidification.
  • step 4 cyclopropylamine g is subject to amide coupling with compound j to afford cyclopropyl amide r, which is a compound of formula I in accordance with the invention.
  • Scheme C shows yet another synthetic route to the compounds of the invention, wherein R is lower alkyl, and Ar 1 , Ar 2 , R 1 , and R 2 are as defined herein.
  • step 1 of Scheme C cinnamate ester compound s is reacted with Witttig reagent t to effect a cyclization reaction and provide cyclopyl ester compound u.
  • Diazomethane may be used in place of Wittig reagent t to prepare compounds where R 1 and R 2 are hydrogen.
  • Cyclopropyl ester u is hydrolized to cyclopropyl acid compound p.
  • Compound p is then converted to an amine g in step 3 and undergoes amide coupling in step 4, following the same procedure of Scheme B, to afford cyclopropyl amide r. Specific details for producing compounds of the invention are described in the Examples section below.
  • the compounds of the invention are usable for the treatment of diseases or conditions associated with the nicotinic alpha 7 ( ⁇ 7nACh) receptor, including treatment of psychotic diseases, neurodegenerative diseases, and cognitive impairments involving a dysfunction of the cholinergic system, and conditions of memory and/or cognition impairment, including, for example, schizophrenia, anxiety, mania, depression, manic depression, Tourette's syndrome, Parkinson's disease, Huntington's disease, cognitive disorders (such as Alzheimer's disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, memory impairment, memory loss, cognition deficit, attention deficit, Attention Deficit Hyperactivity Disorder), and other uses such as treatment of nicotine addiction, inducing smoking cessation, treating pain (i.e., analgesic use), providing neuroprotection, and treating jetlag.
  • the compounds of the invention are useful for enhancing or improving cognition in
  • the invention provides a method of treating a patient or subject, specifically a mammal and especially a human, suffering from psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system, and conditions of memory and/or cognition impairment, including, for example, schizophrenia, anxiety, mania, depression, manic depression [examples of psychotic disorders], Tourette's syndrome, Parkinson's disease, Huntington's disease [examples of neurodegenerative diseases], and/or cognitive disorders (such as Alzheimer's disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, memory impairment, memory loss, cognition deficit, attention deficit, Attention Deficit Hyperactivity Disorder) comprising administering to the patient an effective amount of a compound of the invention.
  • psychotic diseases including, for example, schizophrenia, anxiety, mania, depression, manic depression [examples of psychotic disorders], Tourette's syndrome, Parkinson's disease, Huntington's disease [examples of neurodegenerative diseases]
  • cognitive disorders such as Alzheimer's disease,
  • Neurodegenerative disorders include, but are not limited to, treatment and/or prophylaxis of Alzheimer's diseases, Pick's disease, diffuse Lewy Body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado- Joseph disease/spinocerebellar ataxia type 3, olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar, pseudobulbar palsy, spinal muscular atrophy, spinobulbar muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic para
  • the compounds of the invention may be used to treat age-related dementia and other dementias and conditions with memory loss including age-related memory loss, senility, vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica and frontal lobe dementia.
  • the invention provides a method of treating a patient, especially a human, suffering from age-related dementia and other dementias and conditions with memory loss, as well as enhancing cognitive memory in Alzheimer's patients, comprising administering to the patient an effective amount of a compound of the invention.
  • the invention provides methods of treating subjects suffering from memory impairment due to, for example, Alzheimer's disease, mild cognitive impairment due to aging, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt- Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia and other neurological conditions, as well as HIV and cardiovascular diseases, comprising administering an effective amount of a compound of the invention.
  • Amyloid precursor protein (APP) and A ⁇ peptides derived therefrom, e.g., A ⁇ i_4o , A ⁇ i_4 2 , and other fragments, are known to be involved in the pathology of Alzheimer's disease.
  • the A ⁇ i_42 peptides are not only implicated in neurotoxicity but also are known to inhibit cholinergic transmitter function. Further, it has been determined that A ⁇ peptides bind to ⁇ 7nACh receptors. Agents which block the binding of the A ⁇ peptides to ⁇ -7 nAChRs are thus useful for treating neurodegenerative diseases. In addition, stimulation ⁇ 7nACh receptors can protect neurons against cytotoxicity associated with A ⁇ peptides.
  • the invention provides a method of treating and/or preventing dementia in an Alzheimer's patient which comprises administering to the subject a therapeutically effective amount of a compound according to Formulas I-IV to inhibit the binding of an amyloid beta peptide (preferably, A ⁇ i_4 2 ) with nACh receptors, preferable ⁇ 7nACh receptors, most preferably, human ⁇ 7nACh receptors (as well as a method for treating and/or preventing other clinical manifestations of Alzheimer's disease that include, but are not limited to, cognitive and language deficits, apraxias, depression, delusions and other neuropsychiatric symptoms and signs, and movement and gait abnormalities).
  • an amyloid beta peptide preferably, A ⁇ i_4 2
  • nACh receptors preferable ⁇ 7nACh receptors
  • human ⁇ 7nACh receptors preferably, human ⁇ 7nACh receptors
  • the invention also provides methods for treating other amyloidosis diseases, for example, hereditary cerebral angiopathy, nonneuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle- Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, and Finnish and Iowa amyloidosis.
  • amyloidosis diseases for example, hereditary cerebral angiopathy, nonneuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle- Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, and Finnish and Iowa amyloidosis.
  • Nicotinic receptors have been implicated as playing a role in the body's response to alcohol ingestion, and the compounds of the invention are useful in the treatment of alcohol withdrawal and in anti- intoxication therapy.
  • Agonists for the ⁇ 7nACh receptor subtypes can also be used for neuroprotection against damage associated with strokes and ischemia and glutamate-induced excitotoxicity, and the invention thus provides a method of treating a patient to provide for neuroprotection against damage associated with strokes and ischemia and glutamate-induced excitotoxicity comprising administering to the patient an effective amount of a compound of the invention.
  • Agonists for the ⁇ 7nACh receptor subtypes can also be used in the treatment of nicotine addiction, inducing smoking cessation, treating pain, and treating jetlag, obesity, diabetes, and inflammation, and the invention thus provides a method of treating a patient suffering from nicotine addiction, pain, jetlag, obesity, diabetes, and/or inflammation, or a method of inducing smoking cessation in a patient comprising administering to the patient an effective amount of a compound of the invention
  • the inflammatory reflex is an autonomic nervous system response to an inflammatory signal.
  • the autonomic nervous system responds through the vagus nerve by releasing acetylcholine and activating nicotinic ⁇ 7 receptors on macrophages. These macrophages in turn release cytokines. Dysfunctions in this pathway have been linked to human inflammatory diseases including rheumatoid arthritis, diabetes and sepsis. Macrophages express the nicotinic ⁇ 7 receptor and it is likely this receptor that mediates the cholinergic anti-inflammatory response.
  • compounds of the invention may be useful for treating a patient (e.g., a mammal, such as a human) suffering from an inflammatory disease or disorder, such as, but not limited to, rheumatoid arthritis, diabetes or sepsis.
  • a patient e.g., a mammal, such as a human
  • an inflammatory disease or disorder such as, but not limited to, rheumatoid arthritis, diabetes or sepsis.
  • the compounds of the invention are expected to find utility as analgesics in the treatment of diseases and conditions associated with pain from a wide variety of causes, including, but not limited to, inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injuries (including fractures and sports injuries), and pain associated with functional bowel disorders such as irritable bowel syndrome. Further, compounds of the invention are useful for treating respiratory disorders, including chronic obstructive pulmonary disorder (COPD), asthma, bronchospasm, and the like.
  • COPD chronic obstructive pulmonary disorder
  • labeled derivatives of the compounds of Formulas I-IV can be used in neuroimaging of the receptors within, e.g., the brain.
  • labeled agents in vivo imaging of the receptors can be performed using, e.g., PET imaging.
  • the invention also provides a method of treating a patient suffering from, for example, mild cognitive impairment (MCI), vascular dementia (VaD), age-associated cognitive decline (AACD), amnesia associated w/open-heart-surgery, cardiac arrest, and/or general anesthesia, memory deficits from early exposure of anesthetic agents, sleep deprivation induced cognitive impairment, chronic fatigue syndrome, narcolepsy, AIDS- related dementia, epilepsy-related cognitive impairment, Down's syndrome, Alcoholism related dementia, drug/substance induced memory impairments, Dementia Puglistica (Boxer Syndrome), and animal dementia (e.g., dogs, cats, horses, etc.) comprising administering to the patient an effective amount of a compound of the invention.
  • MCI mild cognitive impairment
  • VaD vascular dementia
  • AACD age-associated cognitive decline
  • amnesia associated w/open-heart-surgery cardiac arrest
  • general anesthesia e.g., a patient's syndrome
  • MCI mild
  • the invention includes pharmaceutical compositions comprising at least one compound of the present invention, or an individual isomer, racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
  • the compounds of the invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1-500 mg daily, preferably 1-100 mg daily, and most preferably 1-30 mg daily, depending upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved.
  • One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this Application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease.
  • Compounds of the invention may be administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • the preferred manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
  • a compound or compounds of the invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages.
  • the pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use.
  • Formulations containing about one (1) milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms.
  • the compounds of the invention may be formulated in a wide variety of oral administration dosage forms.
  • the pharmaceutical compositions and dosage forms may comprise a compound or compounds of the present invention or pharmaceutically acceptable salts thereof as the active component.
  • the pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier may be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component.
  • the active component In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from about one (1) to about seventy (70) percent of the active compound.
  • Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it.
  • Tablets, powders, capsules, pills, cachets, and lozenges may be as solid forms suitable for oral administration.
  • Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations.
  • Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia.
  • Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents.
  • Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.
  • Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compounds of the invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-f ⁇ lled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
  • oily or nonaqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
  • the compounds of the invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • the compounds of the invention may be formulated for administration as suppositories.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.
  • the compounds of the invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • the subject compounds may be formulated for nasal administration.
  • the solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray.
  • the formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.
  • the compounds of the invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration.
  • the compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • the active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluoro carbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas.
  • CFC chlorofluoro carbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by a metered valve.
  • the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
  • a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP).
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatine or blister packs from which the powder may be administered by means of an inhaler.
  • formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.
  • the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial.
  • Compounds in transdermal delivery systems are frequently attached to a skin- adhesive solid support.
  • the compound of interest can also be combined with a penetration enhancer, e.g., Azone (l-dodecylazacycloheptan-2-one).
  • Sustained release delivery systems are inserted subcutaneously into the subdermal layer by surgery or injection.
  • the subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid.
  • the pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • Other suitable pharmaceutical carriers and their formulations are described in Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania. Representative pharmaceutical formulations containing a compound of the present invention are described below.
  • Stepl (E)-2-Cvano-3-phenyl-acrylic acid ethyl ester A mixture of benzaldehyde (0.6 mol, 63.7 g), ethyl cyanoacetate (0.6 mol, 67.8 g) and piperidine (1 mL) in EtOH (60 mL) was stirred overnight. The clear solution was then placed in an ice- water bath to initiate the crystallization. The crystalline material was filtered, washed with EtOH and dried in a vacuum oven at 50° C to give 58.27 g of (E)-2- cyano-3-phenyl-acrylic acid ethyl ester.
  • Trifluoro acetic anhydride 25 g, 0.09 mol was added portionwise over a period of 10 minutes at -10° C, to a solution of iV,jV-dimethyl-isobutyramide (9.16 g) in DCM (100 mL). The resulting mixture was stirred at -10° C for 10 minutes and then a viscous solution of 4-methylstyrene (8.2 g) and collidine (11.9 mL) in DCM (15 mL) was added portionwise at -10° C. The resulting mixture was heated at reflux for 22 hours then cooled and concentrated under reduced pressure. The oil residue was washed with ethyl ether and the organic phase was decanted away.
  • the reaction mixture was stirred at - 78° C for 30 minutes and the resulting yellow solution was stirred at 0° C for 15 minutes; it was then cooled again at -78° C and a solution of N-bromosuccinimide (6.6 g) in THF (85 mL) was added dropwise. The resulting suspension was stirred at 0° C for 30 minutes, and a solution of NaOH (8.43 g) in water (85 mL) was then added. The reaction mixture was allowed to warm up to room temperature and was stirred for 1 hour. Volatiles were then evaporated under reduced pressure.
  • the aqueous residue was extracted with ethyl ether and the combined organic extracts were dried over Na 2 SO 4 , filtered, and evaporated under reduced pressure to give 4.2 g of staring material.
  • the aqueous layer was diluted with water and acidified until pH 1. by addition of concentrated HCl (25 mL). The resulting mixture was stored in at 4° C for 2 days, during which time a yellow solid precipitated. This material was collected by filtration, washed with cold water and dried to give 3 g (40% yield) cyclopropanecarboxylic acid a yellow solid.
  • Ethyl chloroformate (1.2 mL) was added to a solution of trans-2,2-dimGthy ⁇ -3-p-tolyl- cyclopropanecarboxylic acid (2.3 g, 11 mmol) and triethylamine (1.7 mL) in a mixture of acetone (15 mL) and water (2.9 mL).
  • the reaction mixture was stirred for 20 minutes, then a solution of sodium azide (0.81 g) in water (5.8 mL) was added and the resulting mixture was stirred for 45 minutes.
  • the reaction mixture was partitioned between water and toluene (1/1 mixture, 50 mL), and the organic layer was separated, dried over Na 2 SO 4 and filtered.
  • the organic layer was heated at 100° C, then cooled and evaporated under high vacuum to give a tan oil.
  • an aqueous solution of HCl (10 M, 30 mL) was added to this oil.
  • the reaction mixture was allowed to cool to room temperature and was extracted with ethyl ether.
  • the combined organic layers were dried over Na 2 SO 4 , filtered, and evaporated under reduced pressure to give 1.6 g of acid starting material.
  • the aqueous layer was basified by addition of an aqueous solution of NaOH,then extracted with DCM.
  • the organic layer was separated, dried over Na 2 SO 4 , filtered, and evaporated under reduced pressure to give 510 mg of tr ⁇ /?5-2,2-dimethyl-3-/?-tolyl-cyclopropylamine as a brown oil.
  • Chlorosulfonic acid (0.4 mL) was added dropwise to a solution of c ⁇ -5-chloro-iV-(2,2- dimethyl-3-phenyl-cyclopropyl)-2-methoxy-benzamide (119 mg, 0.362 mmol) in chloroform.
  • the reaction mixture was stirred for 30 minutes, then poured into a water/ice/brine mixture and extracted with ethyl ether.
  • the combined organic extracts were dried over Na 2 SO 4 , filtered, and evaporated under reduced pressure.
  • the residue was dissolved in 1,4-dioxane and NH 4 OH (concentrated) was added. The resulting mixture was stirred for 45 minutes, then poured into a mixture of water and brine and extracted with EtOAc.
  • Benzoyl chloride (37 ⁇ L) was added at 0° C to a solution of tra/?s-2,2-dimethyl-3-/?-tolyl- cyclopropylamine (50 mg, 0.28 mmol) in pyridine (1 mL). The reaction mixture was slowly allowed to warm up to room temperature, then was partitioned between an aqueous solution of HCl (1 M) and DCM. The combined organic extracts were washed with a saturated aqueous solution of NaHCCh, dried over Na 2 SO 4 , filtered, and evaporated under reduced pressure to give 50 mg of a tan oil which was purified by preparative HPLC.
  • a Zorbax 3.5 um, 4.6X50mm SB-phenyl column was used with solvent A (water with 0.1%(V/V) formic acid) and solventB (acetonitrile), A/B 75/25 from 0 to 1 minute, A/B 5/95 at 6 minutes, A/B 75/25 at 6.5 minutes, A/B 75/25 at 7.0 minutes, flow rate 1.0 mL/minute.
  • MS 280 [M+H] + .
  • Peak # 1 (1 S.3R) Peak # 2 (1 R,3S)
  • Step 1 7> ⁇ /?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid ethyl ester
  • the reaction mixture was poured onto ice and the resuling aqueous mixture was adjusted to neutral pH by addition of IM aqueous H 2 SO 4 .
  • the aqueous solution was extracted three times with a 1/1 mixture of hexanes/EtOAc and once with EtOAc.
  • the combined organic layers were filtered through silica, and the filtrate was dried over MgSO 4 , filtered, and concentrated under reduced pressure to give 15.22 g of crude £rans-3-(3-methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid ethyl ester.
  • Step 2 7> ⁇ /?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid 7> ⁇ /?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid ethyl ester (15.22 g, 61 mmol) was added to a mixture of EtOH (200 mL) and 2M aqueous NaOH (100 mL). Solid NaOH (5.0 g, 125 mmol) was added, and the reaction mixture was stirred under N 2 atmosphere for 15 hours at room temperature.
  • Step 3 7> ⁇ /?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropylamine 7> ⁇ /?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropylamine was prepared from Trans- 3-(3-methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid following the procedure of step 3 of Preparation 4 above, MS [M+H] + .
  • Example 8 Formulations Pharmaceutical preparations for delivery by various routes are formulated as shown in the following Tables.
  • "Active ingredient” or “Active compound” as used in the Tables means one or more of the Compounds of Formula I.
  • the ingredients are mixed and dispensed into capsules containing about 100 mg each; one capsule would approximate a total daily dosage.
  • the ingredients are combined and granulated using a solvent such as methanol.
  • the formulation is then dried and formed into tablets (containing about 20 mg of active compound) with an appropriate tablet machine.
  • the ingredients are mixed to form a suspension for oral administration.
  • the active ingredient is dissolved in a portion of the water for injection. A sufficient quantity of sodium chloride is then added with stirring to make the solution isotonic. The solution is made up to weight with the remainder of the water for injection, filtered through a 0.2 micron membrane filter and packaged under sterile conditions.
  • the ingredients are melted together and mixed on a steam bath, and poured into molds containing 2.5 g total weight.
  • nasal spray formulations Several aqueous suspensions containing from about 0.025-0.5 percent active compound are prepared as nasal spray formulations.
  • the formulations optionally contain inactive ingredients such as, for example, micro crystalline cellulose, sodium carboxymethylcellulose, dextrose, and the like. Hydrochloric acid may be added to adjust pH.
  • the nasal spray formulations may be delivered via a nasal spray metered pump typically delivering about 50-100 microliters of formulation per actuation. A typical dosing schedule is 2-4 sprays every 4-12 hours.
  • Buffer solutions used in the assay are HBSS FLIPR buffer (Invitrogen), 2mM CaCl 2 (Sigma), 10 mM HEPES (Invitrogen), 2.5mM Probenecid (Sigma), and 0.1% BSA (Sigma)
  • the alpha 7 nAChR assay is a cell-based functional readout designed to determine the effect of test compounds to either directly activate nicotinic receptor channels and/or to modulate activation by the native agonist acetylcholine (ACh, Sigma).
  • ACh native agonist acetylcholine
  • the cell pellet is resuspended in FLIPR buffer at 0.5 x 10 6 /ml and cells dispensed into sample wells of a 96-well poly-d- lysine coated black/clear plate (Becton Dickinson) at 0.5 x 10 5 cells per well.
  • Sample wells are then supplemented with FLUO- 3AM dye (TefLabs, stock solution prepared at 2.5mM in anhydrous DMSO containing 10% Pluronic acid) in FLIPR buffer at l ⁇ M final assay concentration (FAC).
  • Dye loading of cells occurs by incubation of plates for one hour at 37C in a humidified atmosphere containing 4%CO 2 .
  • FLIPR plates are washed using a Biotek EL405 plate washer leaving a residual volume of 0.1 ml FLIPR buffer per sample well.
  • test compound effect on activation of the alpha7 nicotinic receptor channel is done by measurement of cytosolic [Ca 2+ ] elevation as reported by increased FLUO-3 fluorescence using a two addition experimental design and FLIPRTM (Molecular Devices). Following a 30 second baseline recording, test compounds are added online (dilution scheme below) and cell response is recorded for an additional 5 minutes. After a second addition of ACh (30 ⁇ M, FAC), plates are read for an additional 4 minutes.
  • test compounds Multiple concentrations of test compounds are examined in parallel on each 96 well assay plate.
  • test compounds are then diluted serially in FLIPR buffer (using Biomek 2000) resulting in the following test compound FACs : vehicle, 1.00E-4 M, 3.16E-5, 1.00E-5 M, 3.16E-6, 1.00E-6 M, 3.16E-7, 1.00E-7 M.
  • IC50/EC50 Values for IC50/EC50, intrinsic agonist activity and positive allosteric modulation for alpha 7 nAChR were determined using ACTIVITYBASETM data analysis software. For dose-response data, either the fitted mid-point of the curve (inflection) or the point at which the curve crosses a threshold activity value (typically 50% of control) may be used to determine IC50/EC50.
  • the compounds of the invention were determined to be positive allosteric modulators for alpha 7 nAChR.
  • the compound 5-Chloro-N- [(lS,3R)-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy-benzamide showed an EC50 of 0.89, and intrinsic activity of 493.6, and positive allosteric modulation of 469.6.
  • the cognition-enhancing properties of compounds of the invention may be in a model of animal cognition: the novel object recognition task model.
  • 4-Month-old male Wistar rats (Charles River, The Netherlands) were used. Compounds were prepared daily and dissolved in physiological saline and tested at three doses. Administration was always given i.p. (injection volume 1 ml/kg) 60 minutes before Tl. Scopolamine hydrobromide was injected 30 minutes after compound injection. Two equal testing groups were made of 24 rats and were tested by two experimenters. The testing order of doses was determined randomly. The experiments were performed using a double blind protocol. All rats were treated once with each dose condition.
  • the object recognition test was performed as described by Ennaceur, A., Delacour, J., 1988, A new one-trial test for neurobio logical studies of memory in rats. 1 : Behavioral data. Behav. Brain Res. 31, 47- 59.

Abstract

Compounds of the formula (I) wherein Ar1, Ar2, R1 and R2 are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.

Description

CYCLOPROPYL ARYL AMIDE DERIVATIVES AND USES THEREOF
This invention relates to nicotinic acetylcholine receptor ligands (nAChR), and particularly to positive allosteric modulators for the α7 nAChR subtype, and methods of making and using such compounds. One aspect of the invention provides compounds of formula I:
° R KiΛRK2 1 or a pharmaceutically acceptable salt thereof, wherein:
Ar1 and Ar2 each independently is: optionally substituted aryl; or optionally substituted heteroaryl; and
R1 and R2 each independently is: hydrogen; fluoro; Ci_6alkyl; or halo-Ci_6alkyl.
The invention also provides pharmaceutical compositions and methods of using the aforementioned compounds as well as methods to synthesize above compounds.
In another aspect of the invention there is provided a method for preparing a compound of formula r
Figure imgf000002_0001
wherein Ar1, Ar2, R1 and R2 are as defined herein, the method comprising: reacting a cinnamate compound of formula s
MWA/05.08.2008
Figure imgf000003_0001
wherein R is alkyl, with a Wittig reagent of formula t
Figure imgf000003_0002
" to form a cyclopropylester compound of formula u
Figure imgf000003_0003
hydro lyzing the cyclopropyl ester compound of formula u to afford a cyclopropyl acid compound of formula p
Figure imgf000003_0004
treating the cyclopropyl acid compound of formula p with chloro formate ester, followed by sodium azide and acidification, to afford a cyclopropyl amine compound of formula g
Figure imgf000003_0005
reacting the cyclopropyl amine compound of formula g with an acyl reagent of formula j
Ar1-^ X i wherein X is hydroxy, halo or alkoxy, to form the compound of formula r.
Nicotinic acetylcholine receptors (nAChR) are members of the ligand-gated ion channel family. When activated, the conductance of ions across the nicotinic ion channels increases. Nicotinic alpha 7 receptor (alpha 7 nAChR) forms a homopentameric channel in vitro that is highly permeable to calcium cations. Each alpha 7 nAChR has four transmembrane domains, known as Ml, M2, M3, and M4. The M2 domain has been suggested to form the wall lining the channel. Sequence alignment shows that the alpha 7 nAChR is highly conserved during evolution. The M2 domain that lines the channel is identical in protein sequence from chick to human. Alpha 7 nAChR is described by, Revah et al. (1991), Nature, 353, 846-849; Galzi et al. (1992), Nature 359, 500-505; Fucile et al. (2000), PNAS 97(7), 3643-3648; Briggs et al. (1999), Eur. J. Pharmacol 366 (2-3), 301-308; and Gopalakrishnan et al. (1995), Eur. J. Pharmacol. 290(3), 237- 246. The alpha 7 nAChR channel is expressed in various brain regions and is believed to be involved in many important biological processes in the central nervous system (CNS), including learning, memory and attention (Levin et al., Psychopharmacology (1998), 138, 217-230). Alpha 7 nAChR are localized on both presynaptic and postsynaptic terminals and have been suggested to be involved in modulating synaptic transmission. Agonists of alpha 7 nAChR have been shown to improve attention and cognition in Alzheimer's and attention deficit disorder conditions (Wilens et al., Am. J. Psychiatry (1999), 156(12), 1931-1937).
The analgesic effects of nicotine have long been known. Agonists of the alpha 7 nAChR receptor have been shown to modulate production of pro-inflammatory cytokines, including interleukins (ILs), tumor necrosis factor (TNF) alpha, and high-mobility group box (HMGB-I), and to inhibit inflammatory signalling in the CNS (de Jonge et al., Br. J. Pharmacol. (2007), 1-15). The alpha 7 nAChR receptor has a role in modulating CNS pain transmission, and alpha 7 nAChR agonists have shown an antinociceptive effect in an acute pain model (Damaj et al., Neuropharmacol. (2000) 39, 2785-2791. Since acetylcholine (ACh) is an endogenous agonist of alpha 7 nAChR, agonists that act at the same site as ACh can stimulate and possibly block receptor activity through desensitization and competitive blockade processes (Forman et al., BiophysicalJ. (1988), 54(1), 149-158) and lead to prolonged receptor inactivation (Buisson et al., J. Neurosci. (2001), 21(6), 1819-1829). Desensitization limits the duration that the ion channel remains activated during agonist application. Thus the enhancement of Alpha 7 nAChR activity provided by such agonists will also increase competition with ACh, and therefore limit the usefulness of agonists as drugs.
Positive allosteric modulators of the nicotinic alpha 7 receptor channel enhance the activity of ACh and other nicotinic alpha 7 receptor agonists. Positive allosteric modulators activate alpha 7 nAChR when sufficient ACh is present in the central nervous system. Positive allosteric modulators of alpha 7 nAChRs thus are useful for treatment of CNS, pain and inflammatory diseases or conditions, to regulate CNS functions such as cognition, learning, mood, emotion and attention, and control production of pro- inflammatory cytokines associated with pain and inflammatory conditions. There is accordingly a need for new positive allosteric modulators of the the nicotinic alpha 7 receptor channel.
Definitions Unless otherwise stated, the following terms used in this Application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an," and "the" include plural referents unless the context clearly dictates otherwise.
"Agonist" refers to a compound that enhances the activity of another compound or receptor site.
"Alkyl" means the monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having from one to twelve carbon atoms.
"Lower alkyl" refers to an alkyl group of one to six carbon atoms, i.e. Ci-Cβalkyl.
Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl, hexyl, octyl, dodecyl, and the like.
Examples for "branched alkyl" are isopropyl, isobutyl, tert-butyl, and the like. Preferred alkyl is lower alkyl as defined herein.
"Alkylene" means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g., methylene, ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butylene, pentylene, and the like.
"Alkoxy" means a moiety of the formula -OR, wherein R is an alkyl moiety as defined herein. Examples of alkoxy moieties include, but are not limited to, methoxy, ethoxy, isopropoxy, tert-butoxy and the like. "Alkoxyalkyl" means a moiety of the formula -R'-R", where R' is alkylene and R" is alkoxy as defined herein. Exemplary alkoxyalkyl groups include, by way of example, 2- methoxyethyl, 3-methoxypropyl, l-methyl-2-methoxyethyl, l-(2-methoxyethyl)-3- methoxypropyl, and l-(2-methoxyethyl)-3-methoxypropyl. "Alkylcarbonyl" means a moiety of the formula -C(O)-R, where R is alkyl as defined herein.
"Alkylsulfonyl" means a moiety of the formula -SO2-R' where R' is alkyl as defined herein. "Amino" means a moiety of the formula -NRR' where R and R' each independently is hydrogen or alkyl as defined herein.
"Amino sulfonyl" means a moiety of the formula -SO2-R' where R' is amino as defined herein.
"Alkylsulfonylalkyl" means a moiety of the formula -Rb-SO2-Ra, where Ra is alkyl and Rb is alkylene as defined herein. Exemplary alkylsulfonylalkyl groups include, by way of example, 3-methanesulfonylpropyl, 2-methanesulfonylethyl, 2-methanesulfonylpropy, and the like.
"Alkylsulfonyloxy" means a moiety of the formula Ra-SO2-O-, where Ra is alkyl as defined herein. "Antagonist" refers to a compound that diminishes or prevents the action of another compound or receptor site.
"Aryl" means a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono-, bi- or tricyclic aromatic ring. The aryl group can be optionally substituted as defined herein. Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl, oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl, diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl, benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl, benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl, benzomorpholinyl, methylenedioxyphenyl, ethylenedioxyphenyl, and the like, including partially hydrogenated derivatives thereof, each of which may be optionally substituted.
A preferred aryl is optionally substituted phenyl.
"Aryloxy" means a moiety of the formula -OR, wherein R is an aryl moiety as defined herein.
"Arylalkyl" and "Aralkyl", which may be used interchangeably, mean a radical- RaRb where Ra is an alkylene group and Rb is an aryl group as defined herein; e.g., phenylalkyls such as benzyl, phenylethyl, 3-(3-chlorophenyl)-2-methylpentyl, and the like are examples of arylalkyl.
"Aralkoxy" means a moiety of the formula -OR, wherein R is an aralkyl moiety as defined herein. "Cyanoalkyl" means a moiety of the formula -R'-R", where R' is alkylene as defined herein and R" is cyano or nitrile.
"Cycloalkyl" means a monovalent saturated carbocyclic moiety consisting of mono- or bicyclic rings. Cycloalkyl can optionally be substituted with one or more substituents, wherein each substituent is independently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unless otherwise specifically indicated. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like, including partially unsaturated derivatives thereof. "Cycloalkyloxy" and "cycloalkoxy", which may be used interchangeably, mean a group of the formula -OR wherein R is cycloalkyl as defined herein. Exemplary cycloalkyloxy include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like. "Cycloalkylalkyl" means a moiety of the formula -R'-R", where R' is alkylene and R" is cycloalkyl as defined herein. "Cycloalkylalkyloxy" and "cycloalkylalkoxy", which may be used interchangeably, mean a group of the formula -OR wherein R is cycloalkylalkyl as defined herein. Exemplary cycloalkyloxy include cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy and the like.
"Heteroalkyl" means an alkyl radical as defined herein, including a branched C4-Cy-alkyl, wherein one, two or three hydrogen atoms have been replaced with a substituent independently selected from the group consisting of -ORa, -NRbRc, and -S(O)nRd (where n is an integer from 0 to 2), with the understanding that the point of attachment of the heteroalkyl radical is through a carbon atom, wherein Ra is hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; Rb and Rc are independently of each other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; and when n is 0, Rd is hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl, and when n is 1 or 2, Rd is alkyl, cycloalkyl, cycloalkylalkyl, amino, acylamino, monoalkylamino, or dialkylamino. Representative examples include, but are not limited to, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxy-l -hydro xymethylethyl, 2,3- dihydroxypropyl, 1 -hydro xymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl, 2- hydroxy-1-methylpropyl, 2-aminoethyl, 3-aminopropyl, 2-methylsulfonylethyl, aminosulfonylmethyl, aminosulfonylethyl, amino sulfonylpropyl, methylaminosulfonylmethyl, methylaminosulfonylethyl, methylaminosulfonylpropyl, and the like. Preferred heteroalkyl are hydroxyalkyl, alkylhydroxyalkyl, aminoalkyl, mono alky lamino alkyl, and dialkylamino alkyl. "Heteroaryl" means a monocyclic, bicyclic or tricyclic radical of 5 to 12 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring. The heteroaryl ring may be optionally substituted as defined herein. Examples of heteroaryl moieties include, but are not limited to, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, thienyl, thiophenyl, furanyl, pyranyl, pyridinyl, pyrrolyl, pyrazolyl, pyrimidyl, quinolinyl, isoquinolinyl, benzofuryl, benzo furanyl, benzo thiophenyl, benzothiopyranyl, benzimidazolyl, benzo xazo IyI, benzooxadiazolyl, benzo thiazolyl, benzo thiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl, triazinyl, quinoxalinyl, purinyl, quinazolinyl, quinolizinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl, acridinyl and the like, including partially hydrogenated derivatives thereof, each of which may be optionally substituted. Preferred heteroaryl include indolyl, pyridinyl, pyrimidinyl, thienyl, furanyl pyrrolyl, isoxazolyl, imidazolyl and pyrazolyl, each of which may be optionally substituted.
"Heteroarylalkyl" and "heteroaralkyl", which may be used interchangeably, mean a radical-RaRb where Ra is an alkylene group and Rb is a heteroaryl group as defined herein The terms "halo" and "halogen", which may be used interchangeably, refer to a substituent fluoro, chloro, bromo, or iodo. "Haloalkyl" means alkyl as defined herein in which one or more hydrogen has been replaced with same or different halogen. Exemplary haloalkyls include -CH2Cl, -CH2CF3, -CH2CCl3, perfiuoroalkyl (e.g., -CF3), and the like.
"Haloalkoxy" means a moiety of the formula -OR, wherein R is a haloalkyl moiety as defined herein. Examples of haloalkoxy moieties include, but are not limited to, trifluoromethoxy, difluoromethoxy, 2,2,2-trifluoroethoxy, and the like.
"Hydro xyalkyl" refers to a subset of heteroalkyl and refers in particular to an alkyl moiety as defined herein that is substituted with one or more, preferably one, two or three hydroxy groups, provided that the same carbon atom does not carry more than one hydroxy group. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1 -(hydro xymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 2-hydroxy-l- hydroxymethylethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)- 3-hydroxypropyl. "Heterocycloamino" means a saturated ring wherein at least one ring atom is N, NH or
N-alkyl and the remaining ring atoms form an alkylene group.
"Heterocyclyl" means a monovalent saturated moiety, consisting of one to three rings, incorporating one, two, or three or four heteroatoms (chosen from nitrogen, oxygen or sulfur). The heterocyclyl ring may be optionally substituted as defined herein. Examples of heterocyclyl moieties include, but are not limited to, optionally substituted piperidinyl, piperazinyl, homopiperazinyl, azepinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyridinyl, pyridazinyl, pyrimidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinuclidinyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazolylidinyl, benzo thiazolidinyl, benzoazolylidinyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinylsulfoxide, thiamorpholinylsulfone, dihydro quinolinyl, dihydriso quinolinyl, tetrahydro quinolinyl, tetrahydriso quinolinyl, and the like. "Optionally substituted", when used in association with "aryl", phenyl", "heteroaryl" (including indolyl such as indol-1-yl, indol-2-yl and indol-3-yl, 2,3-dihydroindolyl such as 2,3-dihydroindol-l-yl, 2,3-dihydroindol-2-yl and 2,3-dihydroindol-3-yl, indazolyl such as indazol-1-yl, indazol-2-yl and indazol-3-yl, benzimidazolyl such as benzimidazol-1-yl and benzimidazol-2-yl, benzo furanyl such as benzo furan-2-yl and benzo furan-3-yl, benzo thiophenyl such as benzo thiophen-2-yl and benzo thiophen-3-yl, benzoxazol-2-yl, benzo thiazol-2-yl, thienyl, furanyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl and quinolinyl) " or "heterocyclyl", means an aryl, phenyl, heteroaryl or heterocyclyl which is optionally substituted independently with one to four substituents, preferably one or two substituents selected from alkyl, cycloalkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, nitro, heteroalkyl, amino, mono-alkylamino, di-alkylamino, hydroxyalkyl, alkoxyalkyl, alkylsulfonyl, alkylsulfonamido, benzyloxy, cycloalkylalkyl, cycloalkoxy, cycloalkylalkoxy, alkylsulfonyloxy, optionally substituted phenyl, optionally substituted thienyl, optionally substituted pyrazolyl, optionally substituted pyridinyl, morpholinocarbonyl,-(CH2)q-S(O)rRf; -(CH2)q-NRgRh; -(CH2)q-C(=O)-NRgRh; -(CH2)q- C(=O)-C(=O)-NRgRh; -(CH2)q-SO2-NRgRh; -(CH2)q-N(Rf)-C(=O)-R1; -(CH2)q-C(=O)- R1; or -(CH2)q-N(Rf)-SO2-Rg; where q is 0 or 1, r is from 0 to 2, Rf, Rg, and Rh each independently is hydrogen or alkyl, and each R1 is independently hydrogen, alkyl, hydroxy, or alkoxy. Certain preferred optional substituents for "aryl", phenyl", "heteroaryl" "cycloalkyl" or "heterocyclyl" include alkyl, halo, haloalkyl, alkoxy, cyano, amino (i.e. -NH2, -NH(alkyl), -N(alkyl)2), aminosulfonyl (i.e. -SO2NH2, -SO2NH(alkyl),
-SO2N(alkyl)2), alkylsulfonyl and phenyl optionally substituted by 1, 2 or 3 alkoxy, alkyl or halo (preferably by alkoxy). More preferred substituents are methyl, tert-butyl, fluoro, chloro, bromo, trifluoromethyl, methoxy, cyano, aminosulfonyl (i.e. sulfamoyl), methylaminosulfonyl (i.e. methylsulfamoyl), dimethylaminosulfonyl (i.e. dimethylsulfamoyl), methanesulfonyl and methoxyphenyl. More preferred substituents are methyl, fluoro, chloro, trifluoromethyl, methoxy, amino, aminosulfonyl and methanesulfonyl.
"Modulator" means a molecule that interacts with a target. The interactions include, but are not limited to, agonist, antagonist, and the like, as defined herein.
"Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. "Optionally substituted" hence means unsubstituted or substituted with one or more of the substituents as described herein.
"Disease" and "Disease state" means any disease, condition, symptom, disorder or indication.
"Inert organic solvent" or "inert solvent" means the solvent is inert under the conditions of the reaction being described in conjunction therewith, including for example, benzene, toluene, acetonitrile, tetrahydrofuran, N,N-dimethylformamide, chloroform, methylene chloride or dichloromethane, dichloroethane, diethyl ether, ethyl acetate, acetone, methyl ethyl ketone, methanol, ethanol, propanol, isopropanol, tert-butanol, dioxane, pyridine, and the like. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert solvents. "Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use. "Pharmaceutically acceptable salts" of a compound means salts that are pharmaceutically acceptable, as defined herein, and that possess the desired pharmacological activity of the parent compound. Such salts include: acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydro xynaphtoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, p- toluenesulfonic acid, trimethylacetic acid, and the like; or salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic or inorganic base. Acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine, and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide. The preferred pharmaceutically acceptable salts are the salts formed from acetic acid, hydrochloric acid, sulphuric acid, methanesulfonic acid, maleic acid, phosphoric acid, tartaric acid, citric acid, sodium, potassium, calcium, zinc, and magnesium. It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same acid addition salt.
"Solvates" means solvent additions forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate, when the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one of the substances in which the water retains its molecular state as H2O, such combination being able to form one or more hydrate. "Subject" means mammals and non-mammals. Mammals means any member of the mammalia class including, but not limited to, humans; non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, and swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice, and guinea pigs; and the like. Examples of non-mammals include, but are not limited to, birds, and the like. The term "subject" does not denote a particular age or sex.
"Pain" and pain conditions (states) as used herein means pain associated with any of a wide variety of causes, including but not limited to, inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injuries (including fractures and sports injuries), and pain associated with functional bowel disorders such as irritable bowel syndrome. "Inflammation" means any pathological process characterized by injury or destruction of tissues resulting from cytologic reactions, chemical reactions or other causes. Inflammation may be manifested by signs of pain, heat, redness, swelling, and loss of function. Inflammation indications include, but are not limited to, bacterial, fungal or viral infections, rheumatoid arthritis, osteoarthritis, surgery, bladder infection or idiopathic bladder inflammation, over-use, old age, or nutritional deficiencies, prostatis and conjunctivitis.
"Cognition" means any mental process associated with acquiring and retaining knowledge. A "cognition disorder" means any disturbance to the mental process or processes related to thinking, reasoning, judgment ad memory. Cognition disorders may result from or other wise be associated with Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychosis, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, sleep disorders, feeding disorders such as anorexia, bulimia, and obesity, panic attacks, akathisia, attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. "Therapeutically effective amount" means an amount of a compound that, when administered to a subject for treating a disease state, is sufficient to effect such treatment for the disease state. The "therapeutically effective amount" will vary depending on the compound, disease state being treated, the severity or the disease treated, the age and relative health of the subject, the route and form of administration, the judgment of the attending medical or veterinary practitioner, and other factors.
The terms "those defined above" and "those defined herein" when referring to a variable incorporates by reference the broad definition of the variable as well as preferred, more preferred and most preferred definitions, if any.
"Treating" or "treatment" of a disease state includes:
(i) preventing the disease state, i.e. causing the clinical symptoms of the disease state not to develop in a subject that may be exposed to or predisposed to the disease state, but does not yet experience or display symptoms of the disease state.
(ii) inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms, or (iii) relieving the disease state , i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.
The terms "treating", "contacting" and "reacting" when referring to a chemical reaction means adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product. Nomenclature and Structures In general, the nomenclature used in this Application is based on AUTONOM™ v.4.0, a Beilstein Institute computerized system for the generation of IUPAC systematic nomenclature. Chemical structures shown herein were prepared using ISIS® version 2.2. Any open valency appearing on a carbon, oxygen, sulfur or nitrogen atom in the structures herein indicates the presence of a hydrogen atom. Whenever a chiral carbon is present in a chemical structure, it is intended that all stereoisomers associated with that chiral carbon are encompassed by the structure. All patents and publications identified herein are incorporated herein by reference in their entirety.
Compounds of the Invention The invention provides compounds of formula I:
Figure imgf000013_0001
or a pharmaceutically acceptable salt thereof, wherein:
Ar1 and Ar2 each independently is: optionally substituted aryl; or optionally substituted heteroaryl; and R1 and R2 each independently is: hydrogen; fluoro; Ci_6alkyl; or halo-Ci_6alkyl. In certain embodiments the compounds of the invention may be of formula Ia or Ib:
Figure imgf000014_0001
wherein Ar1, Ar2, R1 and R2 are as defined herein.
In certain embodiments of formula I, Ia or Ib, R1 and R2 are H or Ci_6alkyl. In certain embodiments of formula I, Ia or Ib, R1 and R2 are Ci_6alkyl. In certain embodiments of formula I, Ia or Ib, Ar1 and Ar2 are phenyl, indolyl, pyridinyl, pyrimidinyl, thienyl, furanyl pyrrolyl, isoxazolyl, imidazolyl or pyrazolyl, each optionally substituted as described herein.
In certain embodiments of formula I, Ia or Ib, Ar1 and Ar2 are phenyl, pyridinyl, or isoxazolyl, each optionally substituted as described herein. In certain embodiments of formula I, Ia or Ib, Ar1 is phenyl, indolyl, pyridinyl, pyrimidinyl, thienyl, furanyl pyrrolyl, isoxazolyl, imidazolyl or pyrazolyl, each optionally substituted as described herein; and Ar2 is phenyl, optionally substituted as described herein
In certain embodiments of formula I, Ia or Ib, Ar1 is phenyl, pyridinyl, or isoxazolyl, each optionally substituted as described herein; and Ar2 is phenyl optionally substituted as described herein.
In certain embodiments of formula I, Ia or Ib, the optional substituents of Ar1 and Ar2 are independently selected from one, two or three groups of
Ci_6alkyl; halo;
Ci_6alkoxy; halo-Ci_6alkoxy; halo-Ci_6alkyl; hetero-Ci_6alkyl; phenyl, optionally substituted with one or more alkoxy, halo or alkyl; cyano;
Ci_6alkyl-amino; di-C i _6alkyl-amino ; nitro; or -(CRaRb)m-X-R3 wherein:
X is C(O) or S(O)n; m is 0 or 1 ; n is 0, 1 or 2;
Ra and Rb each independently is: hydrogen; or Ci_6alkyl; and R3 is: hydrogen; Ci-6alkyl; Ci_6alkoxy; hetero-Ci_6alkyl; halo-Ci-ealkyl;
C3_7cycloalkyl; aryl; heteroaryl; heterocyclyl; C3-7cycloalkyl-Ci_6alkyl; aryl-Ci-ealkyl; hetero aryl- C i -βalky 1; heterocyclyl-Ci_6alkyl; C3_7cycloalkyloxy; aryloxy; hetero aryloxy; hetero eye Iy Io xy ; C3_7cycloalkyloxy-Ci_6alkyl; aryloxy-Ci_6alkyl; heteroaryloxy-Ci_6alkyl; heterocyclyloxy-Ci_6alkyl; or -NR4R5, wherein: R4 is: hydrogen; or Ci_6alkyl; and
R5 is: hydrogen; Ci_6alkyl; hetero-Ci_6alkyl;
C3-7cycloalkyl; aryl; heteroaryl; heterocyclyl; C3-7cycloalkyl-Ci_6alkyl; aryl-Ci_6alkyl; heteroaryl-Ci_6alkyl; or heterocyclyl-Ci-βalkyl.
In certain embodiments of formula I, Ia or Ib, the optional substituents of Ar1 and Ar2 are independently selected from one, two or three groups of:
Figure imgf000016_0001
halo;
Ci_6alkoxy; halo-Ci_6alkoxy; halo-Ci_6alkyl; phenyl, optionally substituted with one or more alkoxy, halo or alkyl; cyano;
Ci_6alkyl-amino; di-C i _6alkyl-amino ; nitro; or
-(CRaRb)m-X-R3 wherein: m is 0;
X is C(O) or S(O)2; R3 is -NR4R5, and R4 and R5 each independently is: hydrogen; or Ci_6alkyl.
In certain embodiments of formula I, Ia or Ib, the optional substituents of Ar1 and Ar2 are independently selected from one, two or three groups of alkyl, halo, haloalkyl, alkoxy, cyano, amino (i.e. -NH2, -NH(alkyl), -N(alkyl)2), aminosulfonyl (i.e. -SO2NH2, -
SO2NH(alkyl), -SO2N(alkyl)2), alkylsulfonyl and phenyl optionally substituted by 1, 2 or 3 alkoxy, alkyl or halo (preferably by alkoxy).
In certain embodiments of formula I, Ia or Ib, the optional substituents of Ar1 and Ar2 are independently selected from one, two or three groups of methyl, tert-butyl, fluoro, chloro, bromo, trifluoromethyl, methoxy, cyano, aminosulfonyl (i.e. sulfamoyl), methylaminosulfonyl (i.e. methylsulfamoyl), dimethylaminosulfonyl (i.e. dimethylsulfamoyl), methanesulfonyl and methoxyphenyl. In certain embodiments of formula I, Ia or Ib, the optional substituents of Ar1 are independently selected from one, two or three groups of methyl, tert-butyl, fluoro, chloro, trifluoromethyl, methoxy, aminosulfonyl (i.e. sulfamoyl), methanesulfonyl or methoxyphenyl.
In certain embodiments of formula I, Ia or Ib, the optional substituents of Ar2 are independently selected from one, two or three groups of methyl, chloro, bromo, trifluoromethyl, methoxy, cyano, aminosulfonyl (i.e. sulfamoyl), methylaminosulfonyl (i.e. methylsulfamoyl), dimethylaminosulfonyl (i.e. dimethylsulfamoyl), or methanesulfonyl.
In certain embodiments of formula I, Ia or Ib, Ar1 and Ar2 are optionally substituted phenyl. In certain embodiments of formula I, Ia or Ib, Ar1 and Ar2 are phenyl, each of which is optionally substituted with one, two or three groups each independently selected from:
halo;
Ci_6alkoxy; halo-Ci_6alkoxy; halo-Ci_6alkyl; hetero-Ci_6alkyl; cyano;
Ci_6alkyl-amino; di-Ci_6alkyl-amino; nitro; or
-(CRaRb)m-X-R3 wherein: X is C(O) or S(O)n; m is 0 or 1 ; n is 0, 1 or 2;
Ra and Rb each independently is: hydrogen; or Ci_6alkyl; and R3 is: hydrogen; Ci_6alkyl; Ci_6alkoxy; hetero-Ci_6alkyl; halo-Ci-ealkyl;
C3-7cycloalkyl; aryl; heteroaryl; heterocyclyl; C3_7cycloalkyl-Ci_6alkyl; aryl-Ci-ealkyl; hetero aryl- C i -βalky 1; heterocyclyl-Ci_6alkyl; C3-7cycloalkyloxy; aryloxy; hetero aryloxy; hetero eye Iy Io xy ; C3_7cycloalkyloxy-Ci_6alkyl; aryloxy-Ci_6alkyl; heteroaryloxy-Ci_6alkyl; heterocyclyloxy-Ci_6alkyl; or -NR4R5, wherein: R4 is: hydrogen; or Ci_6alkyl; and
R5 is: hydrogen;
hetero-Ci_6alkyl; C3-7cycloalkyl; aryl; heteroaryl; heterocyclyl; C3_7cycloalkyl-Ci_6alkyl; aryl-Ci_6alkyl; heteroaryl-Ci_6alkyl; or heterocyclyl-Ci-βalkyl.
In certain embodiments of formula I, Ia or Ib, Ar1 and Ar2 each are phenyl optionally substituted with one, two or three groups each independently selected from: Ci_6alkyl; halo;
Ci_6alkoxy; halo-Ci_6alkoxy; halo-Ci_6alkyl; hetero-Ci_6alkyl; cyano;
Ci_6alkyl-amino; di-C i _6alkyl-amino ; nitro; and
-(CRaRb)m-X-R3 wherein: m is 0;
X is C(O) or S(O)n; wherein n is 0, 1 or 2; R3 is -NR4R5, and R4 and R5 each independently is: hydrogen; or Ci_6alkyl.
In certain embodiments of formula I, Ia or Ib, Ar1 is phenyl optionally substituted with one, two or three groups each selected independently from halo, halo-Ci_6alkyl, Ci_6alkyl and Ci_6alkoxy.
In certain embodiments of formula I, Ia or Ib, Ar1 is phenyl optionally substituted with one, two or three groups each selected independently from halo and Ci_6alkoxy. In certain embodiments of formula I, Ia or Ib, Ar1 is phenyl substituted one, two or three times with a group or groups independently selected from chloro, fluoro, methyl and methoxy.
In certain embodiments of formula I, Ia or Ib, Ar1 is 5-chloro-2-methoxy-phenyl, 5- chloro-2,4-dimethoxy-phenyl, phenyl, 4-methoxy-phenyl, 4-methoxy-2-methyl-phenyl,
2,5-dimethoxy-phenyl, 4-methoxy-phenyl, 4-chloro-phenyl, 3,4-dichloro-phenyl and 3- chlorophenyl.
In certain embodiments of formula I, Ia or Ib, Ar1 is 4-trifluoromethyl-phenyl, A- aminosulfonyl-phenyl, 4-N-methylamino-phenyl or 4-N,N-dimethylamino-phenyl. In certain embodiments of formula I, Ia or Ib, Ar1 is phenyl substituted once or twice with methoxy and optionally substituted once with chloro.
In certain embodiments of formula I, Ia or Ib, Ar1 is phenyl substituted one, two or three times with a group or groups independently selected from chloro and methoxy.
In certain embodiments of formula I, Ia or Ib, Ar1 is 5-chloro-2-methoxy-phenyl, 5- chloro-2,4-dimethoxy-phenyl, phenyl, 4-methyl-phenyl, 2-methoxy-5-methyl-phenyl, 2- methyl-5-methoxy-phenyl, 4-methoxy-2-methyl-phenyl, 2,5-dimethoxy-phenyl, A- methoxy-phenyl, 4-chloro-phenyl, 3,4-dichloro-phenyl, 3-chloro-phenyl, 2-methoxy- phenyl, 4-tert-butyl-phenyl, 2,4-dimethoxy-phenyl, 3-trifluoromethyl-phenyl, A- methanesulfonyl-phenyl, 4-aminosulfonyl-phenyl, 4-trifluoromethyl-phenyl, 5-fluoro-2- methoxy-phenyl, 2-methoxy-5-trifluoromethyl-phenyl, 2-methoxy-5-tert-butyl-phenyl, A- chloro-2-methoxy-phenyl, 2,4,5-trimethoxy-phenyl, 2,6-dimethoxy-phenyl, or 2,3- dimethoxy-phenyl.
In certain embodiments of formula I, Ia or Ib, Ar1 is optionally substituted heteroaryl.
Preferred heteroaryl include pyridinyl, pyrimidinyl, thienyl, furanyl, thiazolyl, oxazolyl, isothiazolyl and isoxaloyl, each of which may be optionally substituted with one or two groups each selected independently from halo, Ci_6alkyl and Ci_6alkoxy.
In certain embodiments of formula I, Ia or Ib, Ar1 is pyridinyl or isoxaloyl, each of which may be optionally substituted with one or two groups each selected independently from halo, methyl and methoxy. In certain embodiments of formula I, Ia or Ib, Ar2 is phenyl optionally substituted once at the 4-position with halo, Ci_6alkyl, cyano, halo-Ci_6alkyl, Ci_6alkoxy or -(CRaRb)m-X-R3 wherein: m is 0; X is -SO2-; R3 is Ci-βalkyl or -NR4R5, and
R4 and R5 each independently is: hydrogen; or Ci_6alkyl. In certain embodiments of formula I, Ia or Ib, Ar2 is phenyl substituted at the 4-position with cyano, -SO2-NR5R6, or -SO2-CH3.
In certain embodiments of formula I, Ia or Ib, Ar2 is phenyl substituted at the 4-position with -SO2-NR5R6.
In certain embodiments of formula I, Ia or Ib, Ar2 is phenyl substituted at the 4-position with -SO2NH2 or -SO2-CH3.
In certain embodiments of formula I, Ia or Ib, Ar2 is phenyl substituted at the 4-position with -SO2NH2.
In certain embodiments of formula I, Ia or Ib, Ar2 is phenyl substituted at the 4-position with -SO2CH3. In certain embodiments of formula I, Ia or Ib, Ar2 is phenyl, 4-aminosulfonyl-phenyl, A- methylaminosulfonyl-phenyl, 4-dimethylaminosulfonyl-phenyl, 4-trifluoromethyl-phenyl,
4-methyl-phenyl, 4-chloro-phenyl, 4-methanesulfonyl-phenyl, 4-methoxy-phenyl, A- cyano -phenyl or 4-bromo -phenyl.
In certain embodiments of formula I, Ia or Ib, R1 and R2 are Ci_6alkyl. In certain embodiments of formula I, Ia or Ib, one of R1 and R2 is hydrogen and the other is Ci_6alkyl.
In certain embodiments of formula I, Ia or Ib, one of R1 and R2 is hydrogen and the other is methyl or ethyl.
In certain embodiments of formula I, Ia or Ib, R1 and R2 are methyl. In certain embodiments of formula I, Ia or Ib, R1 and R2 are hydrogen.
In certain embodiments of the invention, the subject compounds are of formula II:
Figure imgf000021_0001
wherein: p and q each independently is from 0 to 3; R1 and R2 are d_6alkyl; and R6 and R7 each independently is: Ci_6alkyl; halo;
Ci_6alkoxy; halo-Ci_6alkoxy; halo-Ci_6alkyl; hetero-Ci_6alkyl; cyano;
Ci_6alkyl-amino; di-C i _6alkyl-amino ; nitro; and
-(CRaRb)m-X-R3 wherein: m is 0; X is -SO2-;
R3 is Ci-βalkyl or -NR4R5, and R4 and R5 each independently is: hydrogen; or Ci_6alkyl.
In certain embodiments of the compounds of formula II, R1 and R2 are methyl. In certain embodiments of the compounds of formula II, p is from 1 to 3 and each R6 is independently:
halo;
Ci_6alkoxy; halo-Ci_6alkoxy; or halo-Ci-βalkyl.
In certain embodiments of the compounds of formula II, q is 1 and R7 is C-^alkyl, halo- C-i-βalkyl or -(CRaRb)m-X-R3 wherein: m is 0; X is -SO2-; R3 is Ci-βalkyl or -NR4R5, and
R4 and R5 each independently is: hydrogen; or Ci_6alkyl. In certain embodiments of the compounds of formula II, p is from 1 to 3 and R6 is halo or methoxy.
In certain embodiments of the compounds of formula II, q is 1 and R7 is -SO2NR4R5,
In certain embodiments the compounds of the invention may be of formula Ha or lib:
Figure imgf000023_0001
wherein p, q, R1, R2, R6 and R7 are as defined herein. In certain embodiments of formula II, Ha or lib, R1 and R2 are methyl. In certain embodiments of formula II, Ha or lib, one of R1 and R2 is hydrogen and the other is methyl or ethyl.
In certain embodiments of formula II, Ha or lib, R1 and R2 are hydrogen. In certain embodiments of formula II, Ha or lib, p is from 0 to 3 and each R6 is independently: Ci_6alkyl; halo;
Ci_6alkoxy; halo-Ci_6alkoxy; halo-Ci_6alkyl; hetero-Ci_6alkyl; cyano;
Ci_6alkyl-amino; di-C i _6alkyl-amino ; nitro; and -(CRaRb)m-X-R3 wherein: m is 0; X is -SO2-; R3 is Ci_6alkyl or -NR4R5, and
R4 and R5 each independently is: hydrogen; or
Ci_6alkyl. In certain embodiments of formula II, Ha or lib, q is 1 and R7 is:
halo;
Ci_6alkoxy; halo-Ci_6alkoxy; halo-Ci_6alkyl; hetero-Ci_6alkyl; cyano;
Ci_6alkyl-amino; di-Ci_6alkyl-amino; nitro; and
-(CRaRb)m-X-R3 wherein: m is 0; X is -SO2-; R3 is Ci-βalkyl or -NR4R5, and
R4 and R5 each independently is: hydrogen; or Ci_6alkyl.
In certain embodiments of formula II, Ha or lib, p is from 1 to 3 and each R6 is independently:
halo;
Ci_6alkoxy; halo-Ci_6alkoxy; or halo-Ci-βalkyl.
In certain embodiments of formula II, Ha or lib, p is from 1 to 3 and each R6 is independently methyl, fluoro, chloro, methoxy or trifluoromethyl. In certain embodiments of formula II, Ha or lib, p is from 1 to 3 and each R6 is independently chloro or methoxy. In certain embodiments of formula II, Ha or lib, q is 1 and R7 is halo, cyano;, Ci_6alkyl, halo-Ci_6alkyl Ci_6alkoxy; or -(CRaRb)m-X-R3 wherein: m is 0; X is -SO2-; R3 is Ci-βalkyl or -NR4R5, and R4 and R5 each independently is: hydrogen; or
Ci_6alkyl.
In certain embodiments of formula II, Ha or lib, q is one and R7 is at the 4-position of the phenyl ring.
In certain embodiments of formula II, Ha or lib, q is 1 and R7 is -SO2NR4R5. In certain embodiments of formula II, Ha or lib, q is 1 and R7 is -SO2NH2. In certain embodiments of the invention, the subject compounds are of formula III:
Figure imgf000025_0001
wherein: p is from 0 to 3; each R6 is independently selected from: Ci_6alkyl; halo;
Ci_6alkoxy; halo-Ci_6alkoxy; or halo-Ci_6alkyl; and R7 is: halo; cyano; Ci_6alkyl; Ci_6alkoxy; or -(CRaRb)m-X-R3 wherein: m is 0; X is -SO2-;
R3 is Ci_6alkyl or -NR4R5, and R4 and R5 each independently is: hydrogen; or Ci_6alkyl.
In certain embodiments of the compound of formula III, p is from O to 3; each R6 is independently selected from:
Figure imgf000026_0001
halo;
Ci_6alkoxy; halo-Ci_6alkoxy; or halo-Ci_6alkyl; and R7 is -(CRaRb)m-X-R3 wherein: m is 0; X is -SO2-; R3 is Ci-βalkyl or -NR4R5, and
R4 and R5 each independently is: hydrogen; or d-ealkyl.
In certain embodiments of the compound of formula III, R3 is -SO2NR > 44Rr, 35. In certain embodiments of the compound of formula III, R4 is hydrogen or methyl. In certain embodiments the subject compounds may be of formula Ilia or IHb:
Figure imgf000026_0002
Ilia;
Figure imgf000026_0003
wherein p, R6 and R7 are as defined herein.
In certain embodiments of formula III, Ilia or IHb, p is from 0 to 3 and each R6 is independently:
halo;
Ci_6alkoxy; halo-Ci_6alkoxy; halo-Ci-βalkyl; hetero-Ci_6alkyl; cyano;
Ci_6alkyl-amino; di-C i _6alkyl-amino ; nitro; and
-(CRaRb)m-X-R3 wherein: m is 0;
X is -SO2-;
R3 is Ci-βalkyl or -NR4R5, and
R4 and R5 each independently is: hydrogen; or
Ci_6alkyl.
In certain embodiments of formula III, Ilia or IHb, p is from 1 to 3 and each R6 is independently:
halo;
Ci_6alkoxy; halo-Ci_6alkoxy; or halo-Ci_6alkyl.
In certain embodiments of formula III, Ilia or IHb, p is from 1 to 3 and each R6 is independently methyl, fluoro, chloro, methoxy or trifluoromethyl.
In certain embodiments of formula III, Ilia or IHb, p is 2 or 3 and each R6 is independently chloro or methoxy.
In certain embodiments of formula III, Ilia or IHb, R7 is -(CRaRb)m-X-R3 wherein: m is 0; X is -SO2-;
R3 is Ci-βalkyl or -NR4R5, and
R4 and R5 each independently is: hydrogen; or Ci_6alkyl. In certain embodiments of formula III, Ilia or IHb, R7 is -SO2NR5R6. In certain embodiments of formula III, Ilia or IHb, R7 is -SO2NH2. Where any of R1, R2, R3, R4, R5, R6, R7, Ra or Rb herein are alkyl or contain an alkyl moiety, such alkyl is preferably lower alkyl, i.e. Ci-Cβalkyl, and more preferably Ci- C4alkyl. In another aspect of the invention there is provided a method for preparing a compound of formula r
Figure imgf000028_0001
wherein Ar1, Ar2, R1 and R2 are as defined herein for formulas I, Ia, Ib, II, Ha, lib, III, Ilia and IHb (in all combinations and subsets), the method comprising: reacting a cinnamate compound of formula s
Figure imgf000028_0002
wherein R is alkyl, with a Wittig reagent of formula t
Figure imgf000028_0003
to form a cyclopropylester compound of formula u
Figure imgf000028_0004
hydro lyzing the cyclopropyl ester compound of formula u to afford a cyclopropyl acid compound of formula p
Figure imgf000028_0005
treating the cyclopropyl acid compound of formula p with chloro formate ester, followed by sodium azide and acidification, to afford a cyclopropyl amine compound o f formula g
Figure imgf000028_0006
reacting the cyclopropyl amine compound of formula g with an acyl reagent of formula j O
Ar
X
JI wherein X is hydroxy, halo or alkoxy, to form the compound of formula r.
Representative compounds in accordance with the methods of the invention are shown in Table 1. Compounds identified as "cis" or "trans" were isolated as racemates.
TABLE 1
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Synthesis Compounds of the present invention can be made by a variety of methods depicted in the illustrative synthetic reaction schemes shown and described below. The starting materials and reagents used in preparing these compounds generally are either available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, Volumes 1-5 and Supplemental ; and Organic Reactions, Wiley & Sons: New York, 1991, Volumes 1-40. The following synthetic reaction schemes are merely illustrative of some methods by which the compounds of the present invention can be synthesized, and various modifications to these synthetic reaction schemes can be made and will be suggested to one skilled in the art having referred to the disclosure contained in this Application. The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data. Unless specified to the contrary, the reactions described herein preferably are conducted under an inert atmosphere at atmospheric pressure at a reaction temperature range of from about -78 0C to about 150 0C, more preferably from about 0 0C to about 125 0C, and most preferably and conveniently at about room (or ambient) temperature, e.g., about 2O 0C. Scheme A below illustrates one synthetic procedure usable to prepare compounds of the invention, wherein R is lower alkyl, X is hydroxy, halo or alkoxy, and Ar1, Ar2, R1, and R2 are as defined herein.
Figure imgf000043_0001
SCHEME A
In Scheme A, aryl aldehyde compound a is reacted with cyano ester compound b to afford an arylonitrile ester compound c. This reaction may be carried out in the presence of amine base catalyst. Compound c is treated with nitro compound d step 2 to provide cyclopropyl nitrile ester compound e. In step 3 nitrile ester compound e is hydro lized under basic conditions to give cyclopropyl nitrile acid compound f. In step 4 compound f is heated in the presence of base to afford cyclopropyl nitrile compound g. Nitrile compound g is then converted to cyclopropyl amide compound h in step 5 by treatment of compound g with hydrogen peroxide in the presence of base. In step 6 cyclopropyl amide compound is treated with bromine and NaOH or like base to afford cyclopropyl amine compound i. Amine compound i then undergoes an amide coupling reaction with acid compound j in step 7 to yield compound k, which is a compound of formula I in accordance with the invention. Numerous variations on the procedures of Scheme A are possible and will be readily apparent to those skilled in the art. For example, nitrile compound g may be hydro lized directly to a carboxylic acid compound in step 5, and then treated with ethyl chloro formate followed by azide to form compound i. The amide formation of step 7 may utilize a carbodiimide such as dicyclohexylcarbodiimide, l-(3- dimethylaminopropyl)-3-ethylcarbodiimide methiodide or other diimide as used in conventional amide coupling reactions. Desired stereochemistry may be introduced by selection of appropriate starting materials and/or use of chiral separation techniques. The amine compound i in many embodiments may undergo chromatographic chiral resolution to provide specific enantiomers.
Scheme B below illustrates another synthetic procedure for the compounds of the invention, wherein R is lower alkyl (preferably methyl), X is hydroxy, halo or alkoxy, and Ar1, Ar2, R1, and R2 are as defined herein.
Figure imgf000044_0001
SCHEME B
In step 1 of Scheme B, amide compound m is treated with trifluoro acetic anhydride, followed by styryl compound n, to afford cyclobutanone compound o. In step 2, cyclobutanone o is treated with Lithium bis(trimethylsilyl)amide, followed by n-bromo- succinimide or like brominating agent, then acid, and then base, to afford cyclopropyl acid compound p. Cyclopropyl compound p is converted to amine g in step 3 by treatment with chloro formate ester, followed by sodium azide and acidification. In step 4 cyclopropylamine g is subject to amide coupling with compound j to afford cyclopropyl amide r, which is a compound of formula I in accordance with the invention.
Scheme C shows yet another synthetic route to the compounds of the invention, wherein R is lower alkyl, and Ar1, Ar2, R1, and R2 are as defined herein.
Figure imgf000045_0001
Figure imgf000045_0002
SCHEME C
In step 1 of Scheme C, cinnamate ester compound s is reacted with Witttig reagent t to effect a cyclization reaction and provide cyclopyl ester compound u. Diazomethane may be used in place of Wittig reagent t to prepare compounds where R1 and R2 are hydrogen. Cyclopropyl ester u is hydrolized to cyclopropyl acid compound p. Compound p is then converted to an amine g in step 3 and undergoes amide coupling in step 4, following the same procedure of Scheme B, to afford cyclopropyl amide r. Specific details for producing compounds of the invention are described in the Examples section below.
Utility The compounds of the invention are usable for the treatment of diseases or conditions associated with the nicotinic alpha 7 (α7nACh) receptor, including treatment of psychotic diseases, neurodegenerative diseases, and cognitive impairments involving a dysfunction of the cholinergic system, and conditions of memory and/or cognition impairment, including, for example, schizophrenia, anxiety, mania, depression, manic depression, Tourette's syndrome, Parkinson's disease, Huntington's disease, cognitive disorders (such as Alzheimer's disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, memory impairment, memory loss, cognition deficit, attention deficit, Attention Deficit Hyperactivity Disorder), and other uses such as treatment of nicotine addiction, inducing smoking cessation, treating pain (i.e., analgesic use), providing neuroprotection, and treating jetlag. The compounds of the invention are useful for enhancing or improving cognition in
Alzheimer's patients and patients having cognition impairment or cognitive disorders associated with schizophrenia, anxiety, mania, depression, manic depression, Tourette's syndrome, Parkinson's disease, Huntington's disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, memory impairment, memory loss, cognition deficit, attention deficit or Attention Deficit Hyperactivity Disorder.
Thus, the invention provides a method of treating a patient or subject, specifically a mammal and especially a human, suffering from psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system, and conditions of memory and/or cognition impairment, including, for example, schizophrenia, anxiety, mania, depression, manic depression [examples of psychotic disorders], Tourette's syndrome, Parkinson's disease, Huntington's disease [examples of neurodegenerative diseases], and/or cognitive disorders (such as Alzheimer's disease, Lewy Body Dementia, Amyotrophic Lateral Sclerosis, memory impairment, memory loss, cognition deficit, attention deficit, Attention Deficit Hyperactivity Disorder) comprising administering to the patient an effective amount of a compound of the invention.
Neurodegenerative disorders include, but are not limited to, treatment and/or prophylaxis of Alzheimer's diseases, Pick's disease, diffuse Lewy Body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado- Joseph disease/spinocerebellar ataxia type 3, olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar, pseudobulbar palsy, spinal muscular atrophy, spinobulbar muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic paraplegia, Werdnig-Hoffmann disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, prion diseases (such as Creutzfeldt- Jakob, Gerstmann-Straussler-Scheinker disease, Kuru and fatal familial insomnia), and neurodegenerative disorders resulting from cerebral ischemia or infarction including embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type (including, but not limited to, epidural, subdural, subarachnoid and intracerebral), and intracranial and intravertebral lesions (including, but not limited to, contusion, penetration, shear, compression and laceration).
In addition, the compounds of the invention may be used to treat age-related dementia and other dementias and conditions with memory loss including age-related memory loss, senility, vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica and frontal lobe dementia. Thus, the invention provides a method of treating a patient, especially a human, suffering from age-related dementia and other dementias and conditions with memory loss, as well as enhancing cognitive memory in Alzheimer's patients, comprising administering to the patient an effective amount of a compound of the invention.
The invention provides methods of treating subjects suffering from memory impairment due to, for example, Alzheimer's disease, mild cognitive impairment due to aging, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt- Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, multiinfarct dementia and other neurological conditions, as well as HIV and cardiovascular diseases, comprising administering an effective amount of a compound of the invention. Amyloid precursor protein (APP) and Aβ peptides derived therefrom, e.g., Aβi_4o , Aβi_42 , and other fragments, are known to be involved in the pathology of Alzheimer's disease. The Aβi_42 peptides are not only implicated in neurotoxicity but also are known to inhibit cholinergic transmitter function. Further, it has been determined that Aβ peptides bind to α7nACh receptors. Agents which block the binding of the Aβ peptides to α-7 nAChRs are thus useful for treating neurodegenerative diseases. In addition, stimulation α7nACh receptors can protect neurons against cytotoxicity associated with Aβ peptides. Thus, the invention provides a method of treating and/or preventing dementia in an Alzheimer's patient which comprises administering to the subject a therapeutically effective amount of a compound according to Formulas I-IV to inhibit the binding of an amyloid beta peptide (preferably, Aβi_42) with nACh receptors, preferable α7nACh receptors, most preferably, human α7nACh receptors (as well as a method for treating and/or preventing other clinical manifestations of Alzheimer's disease that include, but are not limited to, cognitive and language deficits, apraxias, depression, delusions and other neuropsychiatric symptoms and signs, and movement and gait abnormalities). The invention also provides methods for treating other amyloidosis diseases, for example, hereditary cerebral angiopathy, nonneuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle- Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, and Finnish and Iowa amyloidosis.
Nicotinic receptors have been implicated as playing a role in the body's response to alcohol ingestion, and the compounds of the invention are useful in the treatment of alcohol withdrawal and in anti- intoxication therapy. Agonists for the α7nACh receptor subtypes can also be used for neuroprotection against damage associated with strokes and ischemia and glutamate-induced excitotoxicity, and the invention thus provides a method of treating a patient to provide for neuroprotection against damage associated with strokes and ischemia and glutamate-induced excitotoxicity comprising administering to the patient an effective amount of a compound of the invention. Agonists for the α7nACh receptor subtypes can also be used in the treatment of nicotine addiction, inducing smoking cessation, treating pain, and treating jetlag, obesity, diabetes, and inflammation, and the invention thus provides a method of treating a patient suffering from nicotine addiction, pain, jetlag, obesity, diabetes, and/or inflammation, or a method of inducing smoking cessation in a patient comprising administering to the patient an effective amount of a compound of the invention
The inflammatory reflex is an autonomic nervous system response to an inflammatory signal. Upon sensing an inflammatory stimulus, the autonomic nervous system responds through the vagus nerve by releasing acetylcholine and activating nicotinic α7 receptors on macrophages. These macrophages in turn release cytokines. Dysfunctions in this pathway have been linked to human inflammatory diseases including rheumatoid arthritis, diabetes and sepsis. Macrophages express the nicotinic α7 receptor and it is likely this receptor that mediates the cholinergic anti-inflammatory response. Therefore, compounds of the invention may be useful for treating a patient (e.g., a mammal, such as a human) suffering from an inflammatory disease or disorder, such as, but not limited to, rheumatoid arthritis, diabetes or sepsis.
The compounds of the invention are expected to find utility as analgesics in the treatment of diseases and conditions associated with pain from a wide variety of causes, including, but not limited to, inflammatory pain, surgical pain, visceral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, neuritis, neuralgias, poisoning, ischemic injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injuries (including fractures and sports injuries), and pain associated with functional bowel disorders such as irritable bowel syndrome. Further, compounds of the invention are useful for treating respiratory disorders, including chronic obstructive pulmonary disorder (COPD), asthma, bronchospasm, and the like.
In addition, due to their affinity to α7nACh receptors, labeled derivatives of the compounds of Formulas I-IV (e.g., C11 or F18 labeled derivatives), can be used in neuroimaging of the receptors within, e.g., the brain. Thus, using such labeled agents in vivo imaging of the receptors can be performed using, e.g., PET imaging. The invention also provides a method of treating a patient suffering from, for example, mild cognitive impairment (MCI), vascular dementia (VaD), age-associated cognitive decline (AACD), amnesia associated w/open-heart-surgery, cardiac arrest, and/or general anesthesia, memory deficits from early exposure of anesthetic agents, sleep deprivation induced cognitive impairment, chronic fatigue syndrome, narcolepsy, AIDS- related dementia, epilepsy-related cognitive impairment, Down's syndrome, Alcoholism related dementia, drug/substance induced memory impairments, Dementia Puglistica (Boxer Syndrome), and animal dementia (e.g., dogs, cats, horses, etc.) comprising administering to the patient an effective amount of a compound of the invention.
Administration and Pharmaceutical Composition
The invention includes pharmaceutical compositions comprising at least one compound of the present invention, or an individual isomer, racemic or non-racemic mixture of isomers or a pharmaceutically acceptable salt or solvate thereof, together with at least one pharmaceutically acceptable carrier, and optionally other therapeutic and/or prophylactic ingredients.
In general, the compounds of the invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Suitable dosage ranges are typically 1-500 mg daily, preferably 1-100 mg daily, and most preferably 1-30 mg daily, depending upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound used, the route and form of administration, the indication towards which the administration is directed, and the preferences and experience of the medical practitioner involved. One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this Application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease. Compounds of the invention may be administered as pharmaceutical formulations including those suitable for oral (including buccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, or parenteral (including intramuscular, intraarterial, intrathecal, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The preferred manner of administration is generally oral using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
A compound or compounds of the invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use. Formulations containing about one (1) milligram of active ingredient or, more broadly, about 0.01 to about one hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms. The compounds of the invention may be formulated in a wide variety of oral administration dosage forms. The pharmaceutical compositions and dosage forms may comprise a compound or compounds of the present invention or pharmaceutically acceptable salts thereof as the active component. The pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from about one (1) to about seventy (70) percent of the active compound. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier, providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges may be as solid forms suitable for oral administration. Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The compounds of the invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-fϊlled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
The compounds of the invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatine and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. The compounds of the invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify. The compounds of the invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. The subject compounds may be formulated for nasal administration. The solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump. The compounds of the invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluoro carbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by a metered valve. Alternatively the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). The powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatine or blister packs from which the powder may be administered by means of an inhaler.
When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient. For example, the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial. Compounds in transdermal delivery systems are frequently attached to a skin- adhesive solid support. The compound of interest can also be combined with a penetration enhancer, e.g., Azone (l-dodecylazacycloheptan-2-one). Sustained release delivery systems are inserted subcutaneously into the subdermal layer by surgery or injection. The subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polylactic acid. The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Other suitable pharmaceutical carriers and their formulations are described in Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania. Representative pharmaceutical formulations containing a compound of the present invention are described below.
Examples
The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.The following abbreviations may be used in the Examples.
ABBREVIATIONS
DCM dichloromethane/methylene chloride
DMF N,N-dimethylformamide
DMAP 4-dimethylaminopyridine
EDC-MeI l-(3-dimethylaminopropyl)-3-ethylcarbodiimide methiodide
EtOAc ethyl acetate
EtOH ethanol tBuOH tert-butanol gc gas chromatography
HMPA hexamethylphosphoramide hplc high performance liquid chromatography mCPBA m-chloroperbenzoic acid
MeCN acetonitrile
NMP N-methyl pyrrolidinone
TEA triethylamine
TFA trifluoro acetic acid
THF tetrahydro furan
LDA lithium diisopropylamine
LHMDS Lithium bis(trimethylsilyl)amide
TBAF tetrabutylammonium fluoride
TLC thin layer chromatography
Preparation 1
2,2-Dimethyl-3-phenyl-cyclopropanecarbonitrile
The synthetic procedure described in this Preparation was carried out according to the process shown in Scheme D.
Figure imgf000054_0001
3/1 cis/trans mixture
SCHEME D
Stepl (E)-2-Cvano-3-phenyl-acrylic acid ethyl ester A mixture of benzaldehyde (0.6 mol, 63.7 g), ethyl cyanoacetate (0.6 mol, 67.8 g) and piperidine (1 mL) in EtOH (60 mL) was stirred overnight. The clear solution was then placed in an ice- water bath to initiate the crystallization. The crystalline material was filtered, washed with EtOH and dried in a vacuum oven at 50° C to give 58.27 g of (E)-2- cyano-3-phenyl-acrylic acid ethyl ester. The mother liquors and the washings were concentrated under reduced pressure; the residue was cooled in an ice-water bath to produce more crystalline product. This material was collected by filtration and washed with hexane, and a mixture EtOH/hexane (1/4), it was then dried in a vacuum oven at 63° C to give 38.01 g of (E)-2-cyano-3-phenyl-acrylic acid ethyl ester (80% combined yield). Step 2 l-Cyano-2,2-dimethyl-3-phenyl-cyclopropanecarboxylic acid ethyl ester
A mixture of (E)-2-cyano-3-phenyl-acrylic acid ethyl ester (83.6 g, 415 mmol), 2- nitropropane (37 g, 415 mmol) and potassium carbonate (57.4 g, 415 mmol) in EtOH (325 mL) was heated at reflux for 4 hours, then heated to 50° C for 18 hours. The reaction mixture was then poured into an aqueous solution of NaCl (15%, 2 L) and extracted with DCM. The organic layer was separated, dried over Na2SO4, filtered, and evaporated under reduced pressure. The residue was purified by distillation under vacuum to give l-cyano-2,2-dimethyl-3-phenyl-cyclopropanecarboxylic acid ethyl ester (64.26 g, 64% yield, pale yellow oil) which distilled at 118° C (oil bath temperature 157° C). Step 3 l-Cyano-2,2-dimethyl-3-phenyl-cyclopropanecarboxylic acid
A solution of potassium carbonate (40 g) in water (125 mL) was added to a solution of 1- cyano-2,2-dimethyl-3-phenyl-cyclopropanecarboxylic acid ethyl ester (64.26 g, 264 mmol) in MeOH (500 mL). The reaction mixture was heated at reflux for 1 hour and then stirred overnight at 85° C. The volatiles where evaporated under reduced pressure, and the residue was diluted with water and washed twice with EtOAc. The phases were separated and the aqueous phase was acidified by addition of HCl (concentrated). Ethyl ether was added and the mixture was carefully extracted. The organic layer was separated, dried over Na2SO4, filtered and evaporated under reduced pressure to give 27.2 g (49% yield) of l-cyano-2,2-dimethyl-3-phenyl-cyclopropanecarboxylic acid as an off-white solid.
Step 4 2,2-Dimethyl-3-phenyl-cyclopropanecarbonitrile
To a solution of l-cyano-2,2-dimethyl-3-phenyl-cyclopropanecarboxylic acid (13.6 g, 63 mmol) in DMSO (125 mL) was added LiCl (10.72 g, 252 mmol) followed by NaHCO3 (7.96 g, 94.5 mmol) and water (4.55 g, 252 mmol). Gas evolution was observed, and within 30 minutes enough solids were dissolved to allow the milky mixture to stir. The reaction mixture was stirred at 170° C for 18 hours, then cooled and poured into a mixture of water and brine (7/1, 800 mL) and extracted with ethyl ether. The combined organic extracts were dried over Na2SO4, filtered and evaporated under reduced pressure to give 7.79 g (76% yield) of 2,2-dimethyl-3-phenyl-cyclopropanecarbonitrile (3/1, cis/trans mixture).
Preparation 2
7>α/?5-2,2-Dimethyl-3-phenyl-cyclopropylamine
The synthetic procedure described in this Preparation was carried out according to the process shown in Scheme E.
Figure imgf000056_0001
3/1 cis/trans mixture 100% (+) trans isomer (±)
SCHEME E
Step 1
7>α/?5-2,2-Dimethyl-3-phenyl-cyclopropanecarboxylic acid
A mixture of 2,2-dimethyl-3-phenyl-cyclopropanecarbonitrile (cis/trans mixture, 3.2 g,
18.7 mmol) and freshly ground KOH (3.143 g, 56.1 mmol) in ethylene glycol was heated at 165° C for 28 hours. The reaction mixture was then cooled and poured into a mixture of water and brine (300 mL). The resulting mixture was extracted 3 times with ethyl ether, the combined organic extracts were dried over Na2SO4, filtered and evaporated under reduced pressure to give 3.36 g (95% yield) of tra/?s-2,2-dimethyl-3-phenyl- cyclopropanecarboxylic acid.
Step 2
7>α/?5-2,2-Dimethyl-3-phenyl-cyclopropylamine
To a solution of £ra/?s-2,2-dimethyl-3-phenyl-cyclopropanecarboxylic acid (1.78 g, 9.4 mmol) in acetone was added water (4 mL) followed, at -5° C, by ethyl chloroformate
(0.982 mL, 10.34 mmol). The reaction mixture was stirred for 20 minutes and then a solution of sodium azide (731 mg, 11.28 mmol) in water (8 mL) was added. The resulting mixture was stirred for 45 minutes and then diluted with a 1 : 1 mixture of water and toluene. The organic layer was separated, dried over Na2SO4, filtered and heated at 100° C for 1 hour. The solvent was then removed under reduced pressure and an aqueous solution of HCl (8 M, 30 mL) was added, and the resulting mixture was heated at reflux for 45 minutes. The reaction mixture was cooled and an aqueous solution of HCl (10%) was added; the resulting mixture was washed with ethyl ether, then basified by addition of NaOH. The resulting mixture was extracted with ethyl ether, and the combined organic extracts were dried over Na2SO4, filtered, and evaporated under reduced pressure to give 1.05 g (70% yield) of trans^^-dimethyl-S-phenyl-cyclopropylamine. Utilizing the procedure above described and the appropriate starting material, trans-2,2- dimethyl-3 -(4-trifluoromethyl-phenyl)-cyclopropylamine was prepared.
Preparation 3
Cz's^^-Dimethyl-S-phenyl-cyclopropylamine
The synthetic procedure described in this Preparation was carried out according to the process shown in Scheme F.
Figure imgf000057_0001
3/1cis/trans mixture
Figure imgf000057_0002
Step l
2,2-Dimethyl-3-phenyl-cyclopropanecarboxylic acid amide Potassium carbonate (467 mg) was added to a solution of 2,2-dimethyl-3-phenyl- cyclopropanecarbonitrile (3/1 cis/trans mixture, 4 g, 23.4 mmol) in DMSO (7 mL). The resulting mixture was cooled to 0° C and an aqueous solution of hydrogen peroxide (30%, 2.8 mL) was added. The reaction mixture was allowed to warm up to room temperature and was stirred overnight. A second aliquot of aqueous solution of hydrogen peroxide (30%, 2.8 mL) was added and the resulting mixture was stirred for 24 hours. A third aliquot of aqueous solution of hydrogen peroxide (30%, 3.0 mL) was added and the resulting mixture was stirred for 3 days. The reaction mixture was poured into brine and extracted with ethyl ether. The organic layer was separated, dried over Na2SO4, filtered, and evaporated under reduced pressure. The crude residue was purified by flash chromatography (0% to 65% of EtOAc in hexane) to give 2.66 of 2,2-dimethyl-3-phenyl- cyclopropanecarboxylic acid amide (2/1 trans/cis mixture), together with 1.125 g of starting material. Step 2
C/5-2,2-Dimethyl-3-phenyl-cyclopropylamine
Bromine (2.2 mL, 42.4 mmol) was added to an aqueous solution of NaOH (10%) at 0° C. The mixture was stirred vigorously, then added to a flask containing cώ-2,2-dimethyl-3- phenyl-cyclopropanecarboxylic acid amide (2.01 g, 10.6 mmol) at 0° C. The reaction mixture was heated to 85° C for 3 hours, then cooled and poured into a mixture of water and brine. The resulting mixture was extracted with ethyl ether, and the combined organic extracts were washed twice with an aqueous solution of HCl (10%). The aqueous layer was basified and extracted with ethyl ether. The combined organic extracts were dried over Na2SO4, filtered, and evaporated under reduced pressure to give 600 mg of 2,2-dimethyl-3-phenyl-cyclopropylamine cis/trans 5/1.
Preparation 4
7>α/?5-2,2-Dimethyl-3-p-tolyl-cyclopropylamine
The synthetic procedure described in this Preparation was carried out according to the process shown in Scheme G.
Figure imgf000058_0001
t, TEA 1000 C
Figure imgf000058_0002
Figure imgf000058_0003
SCHEME G
Step 1
2,2-Dimethyl-3-p-tolyl-cyclobutanone
Trifluoro acetic anhydride (25 g, 0.09 mol) was added portionwise over a period of 10 minutes at -10° C, to a solution of iV,jV-dimethyl-isobutyramide (9.16 g) in DCM (100 mL). The resulting mixture was stirred at -10° C for 10 minutes and then a viscous solution of 4-methylstyrene (8.2 g) and collidine (11.9 mL) in DCM (15 mL) was added portionwise at -10° C. The resulting mixture was heated at reflux for 22 hours then cooled and concentrated under reduced pressure. The oil residue was washed with ethyl ether and the organic phase was decanted away. DCM (75 mL) and water (75 mL) were added to the oil and the mixture was heated at 100° C for 6 hours. The mixture was cooled to room temperature, separated, and the aqueous layer was extracted with DCM. The combined organic extracts were dried over Na2SO4, filtered, and evaporated under reduced pressure to give 35 g of crude oil, which was purified by flash chromatography (5% to 50% of EtOAc in hexane) to give 6.45 g (50% yield) of 2,2-dimethyl-3-p-tolyl- cyclobutanone as a yellow oil. Step 2
7>α/?5-2,2-Dimethyl-3-p-tolyl-cyclopropanecarboxylic acid A solution of lithium bis(trimethylsilyl)amide (1.0 M in THF, 38 mL) was added dropwise over a period of 20 minutes at -78° C to a solution of 2,2-dimethyl-3-/?-tolyl- cyclobutanone (6.4 g, 34 mmol) in THF (340 mL). The reaction mixture was stirred at - 78° C for 30 minutes and the resulting yellow solution was stirred at 0° C for 15 minutes; it was then cooled again at -78° C and a solution of N-bromosuccinimide (6.6 g) in THF (85 mL) was added dropwise. The resulting suspension was stirred at 0° C for 30 minutes, and a solution of NaOH (8.43 g) in water (85 mL) was then added. The reaction mixture was allowed to warm up to room temperature and was stirred for 1 hour. Volatiles were then evaporated under reduced pressure. The aqueous residue was extracted with ethyl ether and the combined organic extracts were dried over Na2SO4, filtered, and evaporated under reduced pressure to give 4.2 g of staring material. The aqueous layer was diluted with water and acidified until pH 1. by addition of concentrated HCl (25 mL). The resulting mixture was stored in at 4° C for 2 days, during which time a yellow solid precipitated. This material was collected by filtration, washed with cold water and dried to give 3 g (40% yield)
Figure imgf000059_0001
cyclopropanecarboxylic acid a yellow solid. Step 3 7>α/?5-2,2-Dimethyl-3-p-tolyl-cyclopropylamine Ethyl chloroformate (1.2 mL) was added to a solution of trans-2,2-dimGthy{-3-p-tolyl- cyclopropanecarboxylic acid (2.3 g, 11 mmol) and triethylamine (1.7 mL) in a mixture of acetone (15 mL) and water (2.9 mL). The reaction mixture was stirred for 20 minutes, then a solution of sodium azide (0.81 g) in water (5.8 mL) was added and the resulting mixture was stirred for 45 minutes. The reaction mixture was partitioned between water and toluene (1/1 mixture, 50 mL), and the organic layer was separated, dried over Na2SO4 and filtered. The organic layer was heated at 100° C, then cooled and evaporated under high vacuum to give a tan oil. To this oil was added an aqueous solution of HCl (10 M, 30 mL), and the resulting mixture was heated at 100° C. The reaction mixture was allowed to cool to room temperature and was extracted with ethyl ether. The combined organic layers were dried over Na2SO4, filtered, and evaporated under reduced pressure to give 1.6 g of acid starting material. The aqueous layer was basified by addition of an aqueous solution of NaOH,then extracted with DCM. The organic layer was separated, dried over Na2SO4, filtered, and evaporated under reduced pressure to give 510 mg of trα/?5-2,2-dimethyl-3-/?-tolyl-cyclopropylamine as a brown oil.
Example 1
5-Chloro-N-(trα/?5-2,2-dimethyl-3-phenyl-cyclopropyl)-2-methoxy-benzamide The synthetic procedure described in this Example was carried out according to the process shown in Scheme H.
Figure imgf000060_0001
SCHEME H
To a solution of trα/?5-2,2-dimethyl-3-phenyl-cyclopropylamine (1.04 g, 6.5 mmol) in DCM was added triethylamine (1.435 g, 14.3 mmol), followed by 5-chloro-2- methoxybenzoic acid (1.446 g, 7.44 mmol) and O-benzotriazol-l-yl-N,N,N',N'- tetramethyluronium tetrafluoroborate (2.696 g, 8.45 mmol). The resulting mixture was stirred at room temperature overnight, then poured into water and extracted with DCM. The combined organic extracts were dried over Na2SO4, filtered, and evaporated under reduced pressure. The crude residue was purified by flash chromatography (0% to 15% of EtOAc in hexane) to give 1.71 g (86% yield) of £rans-5-chloro-iV-(2,2-dimethyl-3- phenyl-cyclopropyl)-2-methoxy-benzamide, MS = 330 [M+H]+. In a similar manner, using the appropriate starting material, the following compounds were prepared:
Cώ-5-Chloro-Λ/-(2,2-dimethyl-3-phenyl-cyclopropyl)-2-methoxy- benzamide,
MS = 330 [M+H]+; 7>α/?5-5-Chloro-Λ/-[2,2-dimethyl-3-(4-trifluoromethyl-phenyl)- cyclopropyl]-2-methoxy-benzamide, MS = 398 [M+H]+; and
7>α/?5-5-Chloro-Λ/-[2,2-dimethyl-3-(4-trifluoromethyl-phenyl)-cyclopropyl]-2,4- dimethoxy-benzamide, MS = 428 [M+H]+. Additional compounds prepared using the above procedure are shown in Table 1.
Example 2 5-Chloro-N-[7>α/?5-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy- benzamide
The synthetic procedure described in this Example was carried out according to the process shown in Scheme I.
Figure imgf000061_0001
SCHEME I
Chlorosulfonic acid (0.4 mL) was added dropwise to a solution of cώ-5-chloro-iV-(2,2- dimethyl-3-phenyl-cyclopropyl)-2-methoxy-benzamide (119 mg, 0.362 mmol) in chloroform. The reaction mixture was stirred for 30 minutes, then poured into a water/ice/brine mixture and extracted with ethyl ether. The combined organic extracts were dried over Na2SO4, filtered, and evaporated under reduced pressure. The residue was dissolved in 1,4-dioxane and NH4OH (concentrated) was added. The resulting mixture was stirred for 45 minutes, then poured into a mixture of water and brine and extracted with EtOAc. The combined organic extracts were dried over Na2SO4, filtered, and evaporated under reduced pressure. The crude residue was recrystallized from DCM to give 10 mg of cώ-5-chloro-Λ/-[2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2- methoxy-benzamide. The mother liquors were evaporated under reduced pressure to give a mixture of cis and trans products. MS = 409 [M+H]+.
In a similar manner, using the appropriate starting materials, the following compounds were prepared:
Cώ-5-Chloro-Λ/-[3-(4-dimethylsulfamoyl-phenyl)-2,2-dimethyl- cyclopropyl]-2-methoxy-benzamide, MS = 437 [M+H]+; and
7>α/?5-5-Chloro-Λ/-[2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2- methoxy-benzamide, MS = 409 [M+H]+. Additional compounds prepared using the above procedure are shown in Table 1.
Example 3
5-Chloro-N-(trα/?5-2,2-dimethyl-3-p-tolyl-cyclopropyl)-2-methoxy-benzamide The synthetic procedure described in this Example was carried out according to the process shown in Scheme J.
Figure imgf000062_0001
SCHEME J l-(3-Dimethylaminopropyl)-3-ethylcarbodiimide methiodide (130 mg) was added at 0° C to a mixture of 7>α/?5-2,2-dimethyl-3-/?-tolyl-cyclopropylamine (70 mg, 0.4 mmol), 5- chloro-2-methoxybenzoic acid (75 mg), and 1 -hydro xy-7-azabenzotriazo Ie (107 mg) in DCM (2 mL). The reaction mixture was stirred at 0° C for 30 minutes, then allowed to warm to room temperature. The mixture was partitioned between an aqueous solution of HCl (1 M) and DCM. The combined organic extracts were washed with a saturated aqueous solution of NaHCCh, dried over Na2SO4, filtered, and evaporated under reduced pressure to give 160 mg of a tan foam. This crude residue was purified by flash chromatography (0% to 100% Et2O in hexane) to give 70 mg of 5-c\ύoro-N-(trans-2,2- dimethyl-3-/?-tolyl-cyclopropyl)-2-methoxy-benzamide, MS = 344 [M+H]+. In a similar manner, utilizing the appropriate starting material, 5-ch\oro-N-(trans-2,2- dimethyl-3-/?-tolyl-cyclopropyl)-2,4-dimethoxy-benzamide was prepared; MS = 374 [M+H]+; MP = 148.3-150.9° C. Additional compounds prepared using the above procedure are shown in Table 1.
Example 4
N-(7>α/?5-2,2-Dimethyl-3-p-tolyl-cyclopropyl)-benzamide
The synthetic procedure described in this Example was carried out according to the process shown in Scheme K.
Figure imgf000063_0001
SCHEME K
Benzoyl chloride (37 μL) was added at 0° C to a solution of tra/?s-2,2-dimethyl-3-/?-tolyl- cyclopropylamine (50 mg, 0.28 mmol) in pyridine (1 mL). The reaction mixture was slowly allowed to warm up to room temperature, then was partitioned between an aqueous solution of HCl (1 M) and DCM. The combined organic extracts were washed with a saturated aqueous solution of NaHCCh, dried over Na2SO4, filtered, and evaporated under reduced pressure to give 50 mg of a tan oil which was purified by preparative HPLC. A Zorbax 3.5 um, 4.6X50mm SB-phenyl column was used with solvent A (water with 0.1%(V/V) formic acid) and solventB (acetonitrile), A/B 75/25 from 0 to 1 minute, A/B 5/95 at 6 minutes, A/B 75/25 at 6.5 minutes, A/B 75/25 at 7.0 minutes, flow rate 1.0 mL/minute. MS = 280 [M+H]+.
In a similar manner, utilizing the appropriate starting material, N-(trans-2,2-dimGthy{-3- /?-tolyl-cyclopropyl)-4-methyl-benzamide was prepared, MS = 294 [M+H]+. Additional compounds prepared using the above procedure are shown in Table 1.
Example 5 5-Chloro-N-[7>α/?5-3-(4-methanesulfonyl-phenyl)-2,2-dimethyl-cyclopropyl]-2- methoxy-benzamide
The synthetic procedure described in this Example was carried out according to the process shown in Scheme L.
Figure imgf000063_0002
SCHEME L
Chlorosulfonic acid (0.17 mL) was added at 0 0C to a solution of 5-chloro-jV-(7>α/?s-2,2- dimethyl-3-phenyl-cyclopropyl)-2-methoxy-benzamide (165 mg, 0.5 mmol) in chloroform (8 mL), and the resulting mixture was stirred at room temperature for 1.5 hour. The reaction was then quenched by addition of ice and the resulting mixture was extracted with diethyl ether. The combined organic extracts were dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue was dissolved in tetrahydrofuran (10 mL) and cooled to 0 0C. Hydrazine (0.05 mL) was added and the resulting mixture was stirred for 18 hours. The reaction mixture was evaporated under reduced pressure and the residue was dissolved in ethanol (15 mL). Sodium acetate (205 mg) and methyl iodide (355 mg) were added and the resulting mixture was heated to reflux for 18 hours. The reaction mixture was then evaporated under reduced pressure and the residue was partitioned between brine and diethyl ether. The combined organic layers were dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. The residue was absorbed onto silica gel and purified by flash chromatography (EtOAc/hexane, 0-25%) to give 37 mg of 5-chloro-N- [trα/?5-3-(4-methanesulfonyl-phenyl)-2,2-dimethyl-cyclopropyl]-2-methoxy-benzamide colorless viscous oil.
Example 6
Chiral separation and absolute configuration determination of 5-Chloro-Λ/-[(lS,3R)-2,2- dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy-benzamide and 5-Chloro-Λ/- r(lR,3S)-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cvclopropyll-2-methoxy-benzamide
Figure imgf000064_0001
Peak # 1 (1 S.3R) Peak # 2 (1 R,3S)
7>α/?5-5-Chloro-Λ/-[2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy- benzamide was purified by preparative chiral HPLC through multiple injections on a Chiralpak AD preparative column (20 mm ID by 250 mm length, 10 micron packing) using 100% EtOH at 6 ml/min over 30 minutes to give the two enantiomers:
- Peak # 1 retention time 8.9 minutes (-)-enantiomer 883 mg; and
- Peak # 2 retention time 16.9 minutes (+)-enantiomer 875 mg.
These two samples were recrystallized separately. The (-)-enantiomer was recrystallized from EtOH (7 mL), and the solid was dried overnight over P2O5 at 55° C. This material was then re-dissolved in EtOAc and evaporated under reduced pressure three times. The resulting material was then dissolved in DCM and evaporated under reduced pressure four times. The material thus obtained was dried overnight in a drying pistol over refluxing acetone under reduced pressure to give 634.5 mg of a foam, MP = 96.3-102.1° C, αD = -109.7° (c = 0.518, MeOH).
The (+)-Enantiomer (875 mg) was dissolved in DCM and evaporated under reduced pressure at 60° C three times. The resulting solid was dissolved in DCM and hexane was added. The resulting solution was evaporated under reduced pressure at 65° C, and this operation was repeated three times to give a foam that was dried under high vacuum overnight. A portion of this material (182 mg) was recrystallized from 2-propanol to give crystals containing one mole of 2-propanol per mole of solvate. The crystal structure of this material was solved by X-ray diffraction and it allowed the determination of the absolute IR, 3S configuration shown above, a∑> = +86.2° (c = , MeOH).
Example 7 5 -Chloro-2-methoxy-N- [trans-3 -(3 -methoxy-phenyl)-2,2-dimethyl-cyclopropyl] - benzamide
The synthetic procedure described in this Example was carried out according to the process shown in Scheme M.
Figure imgf000065_0001
SCHEME M
Step 1 7>α/?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid ethyl ester
Cyclopropanation of 3-methoxy-cinnamic acid methyl ester was carried out following the procedure of Ahmand et al, J. Med. Chem 2001, 44, 3302-3310. Isopropyl- triphenylphosphonium iodide was prepared as described by Grieco et al., Tet. Lett. 1972, 36, 3781-3783. Briefly, a solution of 3-methoxy-cinnamic acid ethyl ester (14.6 g, 70.9 mmol) in 300 mL THF was cooled in a dry ice/acetone bath to approximately-78 0C, and added dropwise to a -78 0C stirring solution of isopropyl-triphenylphosphonium iodide (51 g. 118 mmol) and n-butyl- lithium (54 mL, 135 mmol) in THF. The reaction mixture was allowed to warm to O0C with stirring for two hours, then was stirred at room temperature for 15 hours. The reaction mixture was poured onto ice and the resuling aqueous mixture was adjusted to neutral pH by addition of IM aqueous H2SO4. The aqueous solution was extracted three times with a 1/1 mixture of hexanes/EtOAc and once with EtOAc. The combined organic layers were filtered through silica, and the filtrate was dried over MgSO4, filtered, and concentrated under reduced pressure to give 15.22 g of crude £rans-3-(3-methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid ethyl ester.
Step 2 7>α/?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid 7>α/?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid ethyl ester (15.22 g, 61 mmol) was added to a mixture of EtOH (200 mL) and 2M aqueous NaOH (100 mL). Solid NaOH (5.0 g, 125 mmol) was added, and the reaction mixture was stirred under N2 atmosphere for 15 hours at room temperature. The reaction mixture was diluted with water and extracted twice with a mixture of 1/1 hexanes/diethyl ether and once with EtOAc. The combined organic layers were dried (MgSO4), filtered, and concentrated under reduced pressure to give 11.5 g of tra/?s-3-(3-methoxy-phenyl)-2,2- dimethyl-cyclopropanecarboxylic acid, MS = 221 [M+H]+. Step 3 7>α/?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropylamine 7>α/?5-3-(3-Methoxy-phenyl)-2,2-dimethyl-cyclopropylamine was prepared from Trans- 3-(3-methoxy-phenyl)-2,2-dimethyl-cyclopropanecarboxylic acid following the procedure of step 3 of Preparation 4 above, MS = [M+H]+.
Step 4 5-Chloro-2-methoxy-N-[(Trans-3-(3-methoxy-phenyl)-2,2-dimethyl- cyclopropyl] -benzamide
5 -Chloro-2-methoxy-N- [trans-3 -(3 -methoxy-phenyl)-2,2-dimethyl-cyclopropyl] - benzamide was prepared by reaction of (£rans-3-(3-Methoxy-phenyl)-2,2-dimethyl- cyclopropylamine with 3-chloro-5-methoxy-benzoic acid following the procedure of Example 3, MS = 360 [M+H]+.
Example 8 Formulations Pharmaceutical preparations for delivery by various routes are formulated as shown in the following Tables. "Active ingredient" or "Active compound" as used in the Tables means one or more of the Compounds of Formula I.
Composition for Oral Administration
Figure imgf000066_0001
The ingredients are mixed and dispensed into capsules containing about 100 mg each; one capsule would approximate a total daily dosage.
Composition for Oral Administration
Ingredient % wtJwt.
Active ingredient 20.0%
Magnesium stearate 0.5%
Crosscarmellose sodium 2.0%
Lactose 76.5%
PVP (polyvinylpyrrolidine) 1.0%
The ingredients are combined and granulated using a solvent such as methanol. The formulation is then dried and formed into tablets (containing about 20 mg of active compound) with an appropriate tablet machine.
Com osition for Oral Administration
Figure imgf000067_0001
The ingredients are mixed to form a suspension for oral administration.
Parenteral Formulation
Figure imgf000067_0002
The active ingredient is dissolved in a portion of the water for injection. A sufficient quantity of sodium chloride is then added with stirring to make the solution isotonic. The solution is made up to weight with the remainder of the water for injection, filtered through a 0.2 micron membrane filter and packaged under sterile conditions.
Figure imgf000067_0003
Figure imgf000068_0002
The ingredients are melted together and mixed on a steam bath, and poured into molds containing 2.5 g total weight.
Figure imgf000068_0001
All of the ingredients, except water, are combined and heated to about 600C with stirring. A sufficient quantity of water at about 600C is then added with vigorous stirring to emulsify the ingredients, and water then added q.s. about 100 g.
Nasal Spray Formulations
Several aqueous suspensions containing from about 0.025-0.5 percent active compound are prepared as nasal spray formulations. The formulations optionally contain inactive ingredients such as, for example, micro crystalline cellulose, sodium carboxymethylcellulose, dextrose, and the like. Hydrochloric acid may be added to adjust pH. The nasal spray formulations may be delivered via a nasal spray metered pump typically delivering about 50-100 microliters of formulation per actuation. A typical dosing schedule is 2-4 sprays every 4-12 hours.
Example 9 Nicotinic alpha 7 Modulation Assay
Cell Cultures
Cell Culture Growth Media: FlO medium (Invitrogen), 2.5% Fetal Bovine Serum (FBS, Summit Biotechnology); 15% heat inactivated donor Horse Serum (Invitrogen), 250 μg/ml Hygromycin B (Invitrogen); and 10OnM Methyllicaconite (MLA, Sigma) are added to each new culture by 50-fold dilution of stock solution prepared in H2O at 5μM. GH4C1 cells (rat pituitary-derived cell line) stably expressing human nicotinic alpha7 WT receptor (RPA clone #34.7) are cultivated in cell culture growth media (described above) at 37C in a humidified atmosphere containing 4%CO2. Fresh cell stock cultures are initiated with cells at 0.1-0.2 x 106/ml, 50 ml media per T225 flask and are grown for 2 or
3 days prior to use in FLIPR assay. Cells harvested two days after intiation of stock flask typically yields ~25 x 106/ T225 flask and 3 days after intiation of stock flask typically yields -40 x 106/ T225 flask. One day prior to assay, cells are placed in in fresh cell culture growth media supplemented with 10OnM fresh MLA. To accomplish media change, suspension cells of the culture are removed and 45 ml fresh cell culture growth media (containing 10OnM fresh MLA) is immediately added to the stock flask as large numbers of cells remain adherent to the surface. The cells in suspension are then collected by centrifugation, resuspended in 5 ml fresh cell culture growth media and returned to the original culture flask.
Buffer Solutions
Buffer solutions used in the assay are HBSS FLIPR buffer (Invitrogen), 2mM CaCl2 (Sigma), 10 mM HEPES (Invitrogen), 2.5mM Probenecid (Sigma), and 0.1% BSA (Sigma)
FLIPR Assay
The alpha 7 nAChR assay is a cell-based functional readout designed to determine the effect of test compounds to either directly activate nicotinic receptor channels and/or to modulate activation by the native agonist acetylcholine (ACh, Sigma). On day one of the assay, attached cells are lifted using lx-concentration Versene (Gibco, Cat-No. 15040), combined with cells in suspension, and collected by centrifugation (5 min, 162 x g). The cell pellet is resuspended in FLIPR buffer at 0.5 x 106/ml and cells dispensed into sample wells of a 96-well poly-d- lysine coated black/clear plate (Becton Dickinson) at 0.5 x 105 cells per well. Sample wells are then supplemented with FLUO- 3AM dye (TefLabs, stock solution prepared at 2.5mM in anhydrous DMSO containing 10% Pluronic acid) in FLIPR buffer at lμM final assay concentration (FAC). Dye loading of cells occurs by incubation of plates for one hour at 37C in a humidified atmosphere containing 4%CO2. To remove extracellular dye, FLIPR plates are washed using a Biotek EL405 plate washer leaving a residual volume of 0.1 ml FLIPR buffer per sample well.
Assay of test compound effect on activation of the alpha7 nicotinic receptor channel is done by measurement of cytosolic [Ca2+] elevation as reported by increased FLUO-3 fluorescence using a two addition experimental design and FLIPR™ (Molecular Devices). Following a 30 second baseline recording, test compounds are added online (dilution scheme below) and cell response is recorded for an additional 5 minutes. After a second addition of ACh (30μM, FAC), plates are read for an additional 4 minutes. Test Compound Preparation
Multiple concentrations of test compounds are examined in parallel on each 96 well assay plate. In order to achieve 100 μM (1.00E-4 M) for the highest FAC of test compound, 24 μl of 10 mM test compound stock solution (100% DMSO) is added directly to 576 μl of FLIPR buffer (i.e. highest [test compound] =0.4 mM = 4-fold FAC). Starting with the 0.4 mM test compound sample, test compounds are then diluted serially in FLIPR buffer (using Biomek 2000) resulting in the following test compound FACs : vehicle, 1.00E-4 M, 3.16E-5, 1.00E-5 M, 3.16E-6, 1.00E-6 M, 3.16E-7, 1.00E-7 M.
Maximum FAC for DMSO = 1% in the sample wells exposed to the the highest FAC of test compound of 100 μM. Negative controls were madeby vehicle addition, followed by ACh addition. Positive controls were made by lμM PNU-120596 addition, followed by ACh addition. Compound Activity
Values for IC50/EC50, intrinsic agonist activity and positive allosteric modulation for alpha 7 nAChR were determined using ACTIVITYBASE™ data analysis software. For dose-response data, either the fitted mid-point of the curve (inflection) or the point at which the curve crosses a threshold activity value (typically 50% of control) may be used to determine IC50/EC50.
Using the above assay, the compounds of the invention were determined to be positive allosteric modulators for alpha 7 nAChR. For example, the compound 5-Chloro-N- [(lS,3R)-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy-benzamide showed an EC50 of 0.89, and intrinsic activity of 493.6, and positive allosteric modulation of 469.6.
Further biological data are shown in the table below:
Figure imgf000070_0001
Figure imgf000071_0001
Example 10
Cognition Enhancement
The cognition-enhancing properties of compounds of the invention may be in a model of animal cognition: the novel object recognition task model. 4-Month-old male Wistar rats (Charles River, The Netherlands) were used. Compounds were prepared daily and dissolved in physiological saline and tested at three doses. Administration was always given i.p. (injection volume 1 ml/kg) 60 minutes before Tl. Scopolamine hydrobromide was injected 30 minutes after compound injection. Two equal testing groups were made of 24 rats and were tested by two experimenters. The testing order of doses was determined randomly. The experiments were performed using a double blind protocol. All rats were treated once with each dose condition. The object recognition test was performed as described by Ennaceur, A., Delacour, J., 1988, A new one-trial test for neurobio logical studies of memory in rats. 1 : Behavioral data. Behav. Brain Res. 31, 47- 59.
While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

Claims

1. A compound of formula I :
Figure imgf000072_0001
or a pharmaceutically acceptable salt thereof, wherein:
Ar1 and Ar2 each independently is: optionally substituted aryl; or optionally substituted heteroaryl; and R1 and R2 each independently is: hydrogen; fluoro; Ci_6alkyl; or halo-Ci_6alkyl.
2. The compound of claim 1, wherein R1 and R2 are Ci_6alkyl.
3. The compound of claim 1 or 2, wherein Ar1 and Ar2 are each independently phenyl, indolyl, pyridinyl, pyrimidinyl, thienyl, furanyl pyrrolyl, isoxazolyl, imidazolyl or pyrazolyl, each optionally substituted with one, two or three groups independently selected from
Ci_6alkyl; halo;
Ci_6alkoxy; halo-Ci_6alkoxy; halo-Ci_6alkyl; hetero-Ci_6alkyl; phenyl, optionally substituted with one or more alkoxy, halo or alkyl; cyano; Ci_6alkyl-amino; di-C i _6alkyl-amino ; nitro; or -(CRaRb)m-X-R3 wherein:
X is C(O) or S(O)n; m is 0 or 1 ; n is 0, 1 or 2; Ra and Rb each independently is: hydrogen; or Ci_6alkyl; and R3 is: hydrogen; Ci-βalkyl;
Ci_6alkoxy; hetero-Ci_6alkyl; halo-Ci-βalkyl; C3_7cycloalkyl; aryl; heteroaryl; heterocyclyl; C3-7cycloalkyl-Ci_6alkyl; aryl-Ci-ealkyl; heteroaryl-Ci_6alkyl; heterocyclyl-Ci_6alkyl; C3_7cycloalkyloxy; aryloxy; heteroaryloxy; heterocyclyloxy;
C3_7cycloalkyloxy-Ci_6alkyl; aryloxy-Ci_6alkyl; hetero arylo xy- C i -βalky 1; heterocyclyloxy-Ci_6alkyl; or -NR4R5, wherein:
R4 is: hydrogen; or Ci_6alkyl; and R5 is: hydrogen;
Ci_6alkyl; hetero-Ci_6alkyl; C3_7Cycloalkyl; aryl; heteroaryl; heterocyclyl; C3-7cycloalkyl-Ci_6alkyl; aryl-Ci_6alkyl; heteroaryl-Ci_6alkyl; or heterocyclyl-Ci-βalkyl.
4. The compound of any one of claims 1 to 3, wherein Ar1 and Ar2 are optionally substituted phenyl.
5. The compound of any one of claims 1 to 4, wherein Ar1 is phenyl optionally substituted with one, two or three groups each selected independently from halo, halo-Ci_ βalkyl, Ci_6alkyl and Ci_6alkoxy.
6. The compound of any one of claims 1 to 5, wherein Ar1 is 5-chloro-2-methoxy- phenyl, 5-chloro-2,4-dimethoxy-phenyl, phenyl, 4-methyl-phenyl, 2-methoxy-5-methyl- phenyl, 2-methyl-5-methoxy-phenyl, 4-methoxy-2-methyl-phenyl, 2,5-dimethoxy-phenyl, 4-methoxy-phenyl, 4-chloro-phenyl, 3,4-dichloro-phenyl, 3-chloro-phenyl, 2-methoxy- phenyl, 4-tert-butyl-phenyl, 2,4-dimethoxy-phenyl, 3-trifluoromethyl-phenyl, A- methanesulfonyl-phenyl, 4-aminosulfonyl-phenyl, 4-trifluoromethyl-phenyl, 5-fluoro-2- methoxy-phenyl, 2-methoxy-5-trifluoromethyl-phenyl, 2-methoxy-5-tert-butyl-phenyl, A- chloro-2-methoxy-phenyl, 2,4,5-trimethoxy-phenyl, 2,6-dimethoxy-phenyl, or 2,3- dimethoxy-phenyl.
7. The compound of any one of claims 1 to 6, wherein Ar2 is phenyl optionally substituted once at the 4-position with halo, Chalky!, cyano, halo-Ci_6alkyl, Ci_6alkoxy or -(CRaRb)m-X-R3 wherein: m is 0; X is -SO2- or -C(O)-; R3 is Ci-βalkyl or -NR4R5, and
R4 and R5 each independently is: hydrogen; or Ci_6alkyl.
8. The compound of any one of claims 1 to 7, wherein Ar2 is phenyl substituted at the 4-position with cyano, -SO2NH2 or -SO2-CH3.
9. The compound of any one of claims 1 to 8, wherein Ar2 is phenyl, 4- aminosulfonyl-phenyl, 4-methylaminosulfonyl-phenyl, 4-dimethylaminosulfonyl-phenyl, 4-trifluoromethyl-phenyl, 4-methyl-phenyl, 4-chloro-phenyl, 4-methanesulfonyl-phenyl, 4-methoxy-phenyl, 4-cyano-phenyl or 4-bromo-phenyl.
10. The compound of claim 1, wherein the compound is selected from 5-Chloro-N-[trα/?5-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy- benzamide;
5-Chloro-N-[(lR,3S)-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy- benzamide;
5-Chloro-N-[(lS,3R)-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy- benzamide;
5-Chloro-N-[trα/?5-2,2-dimethyl-3-(4-trifluoromethyl-phenyl)-cyclopropyl]-2-methoxy- benzamide;
5-Chloro-N-[trα/?5-2,2-dimethyl-3-phenyl-cyclopropyl]-2-methoxy-benzamide;
5-Chloro-N-[trα/?5-2,2-dimethyl-3-(4-trifluoromethyl-phenyl)-cyclopropyl]-2,4- dimethoxy-benzamide;
5-Chloro-N-[trα/?5-2,2-dimethyl-3-p-tolyl-cyclopropyl]-2-methoxy-benzamide;
5-Chloro-N-[trα/?5-2,2-dimethyl-3-p-tolyl-cyclopropyl]-2,4-dimethoxy-benzamide;
5-Chloro-N-[3-(4-chloro-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-2-methoxy-benzamide;
5-Chloro-N-[3-(4-methanesulfonyl-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-2-methoxy- benzamide;
5-Chloro-N-[trα/?5-2,2-dimethyl-3-phenyl-cyclopropyl]-2,4-dimethoxy-benzamide;
N-[trα/?5-2,2-Dimethyl-3-p-tolyl-cyclopropyl]-4-methyl-benzamide;
N-[trα/?5-2,2-Dimethyl-3-p-tolyl-cyclopropyl]-2-methoxy-5-methyl-benzamide;
N-[trα/?5-2,2-Dimethyl-3-p-tolyl-cyclopropyl]-4-methoxy-2-methyl-benzamide; N-[trans-2,2-Dimethyl-3-p-tolyl-cyclopropyl]-4-methoxy-benzamide;
4-Chloro-N-[£rans-2,2-dimethyl-3-p-tolyl-cyclopropyl]-benzamide;
3,4-Dichloro-N-[(trα/?5-2,2-dimethyl-3-p-tolyl-cyclopropyl]-benzamide;
5-Chloro-2,4-dimethoxy-N-[3-(4-methoxy-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]- benzamide;
5-Chloro-2-methoxy-N-[3-(4-methoxy-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]- benzamide;
2-Methoxy-N-[3-(4-methoxy-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-5-methyl- benzamide; 4-Methoxy-N-[3-(4-methoxy-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-2-methyl- benzamide;
2,5-Dimethoxy-N-[3-(4-methoxy-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-benzamide;
N-[3-(4-Chloro-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-4-methyl-benzamide;
N-[3-(4-Chloro-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-benzamide; 3,4-Dichloro-N-[3-(4-chloro-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-benzamide;
4-Chloro-N-[3-(4-chloro-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-benzamide;
N-[3-(4-Chloro-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-4-methoxy-benzamide;
N-[3-(4-Methoxy-phenyl)-trα/75-2,2-dimethyl-cyclopropyl]-4-methyl-benzamide;
4-Chloro-N-[3-(4-methoxy-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-benzamide; 4-Methoxy-N-[3-(4-methoxy-phenyl)-trα/?5-2,2-dimethyl-cyclopropyl]-benzamide;
5-Chloro-N-[(lS,3R)-2,2-dimethyl-3-(4-methylsulfamoyl-phenyl)-cyclopropyl]-2- methoxy-benzamide;
5-Chloro-N-[(lS,3R)-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2,4-dimethoxy- benzamide; 5-Chloro-N-[(lS,3R)-2,2-dimethyl-3-(4-methylsulfamoyl-phenyl)-cyclopropyl]-2,4- dimethoxy-benzamide;
5-Chloro-N-[3-(4-methanesulfonyl-phenyl)-(lS,3R)-2,2-dimethyl-cyclopropyl]-2- methoxy-benzamide;
5-Chloro-N-[trα/?5-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2,4-dimethoxy- benzamide;
3-Chloro-N-[trα/?5-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-benzamide;
N-[trα/?5-2,2-Dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy-benzamide;
4-tert-Butyl-N-[trα/?5-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-benzamide;
N-[7>α/?5-2,2-Dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2,4-dimethoxy-benzamide; N- [ Trans-2,2-DimQthyl-3 -(4-sulfamoyl-phenyl)-cyclopropyl] -3 -trifluoromethyl- benzamide;
3,4-Dichloro-N-[trα/?5-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-benzamide;
5-Chloro-2-methoxy-N-[trα/?5-2-methyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-benzamide; 5-Chloro-N-[trα/?5-2-ethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy-benzamide;
N- [ Trans-2,2-DimQthyl-3 -(4-sulfamoyl-phenyl)-cyclopropyl] -5 -fluoro-2-methoxy- benzamide;
N- [ Trans-2,2-DimQthyl-3 -(4-sulfamoyl-phenyl)-cyclopropyl] -5 -methoxy-2-methyl- benzamide; N-[(lS,3R)-2,2-Dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2,4-dimethoxy- benzamide;
Figure imgf000077_0001
trifluoromethyl-benzamide;
5 -tert-Butyl-N- [trans-2,2-dimethyl-3 -(4-sulfamoyl-phenyl)-cyclopropyl] -2-methoxy- benzamide;
N- [ Trans-2,2-DimQthyl-3 -(4-sulfamoyl-phenyl)-cyclopropyl] -2,4-dimethoxy-5 -methyl- benzamide;
Figure imgf000077_0002
benzamide; N-[7>α/?5-2,2-Dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2,6-dimethoxy- nicotinamide;
N- [ Trans-2,2-DimQthyl-3 -(4-sulfamoyl-phenyl)-cyclopropyl] -5 -fluoro-2-methoxy- benzamide;
5-Chloro-N-[trα/?5-3-(4-cyano-phenyl)-2,2-dimethyl-cyclopropyl]-2-methoxy-benzamide; 4-Chloro-N-[trα/?5-2,2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy- benzamide;
5-Chloro-N-[2(trα/?5-2-dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy- nicotinamide;
5-Chloro-N-[trα/?5-3-(4-methanesulfonyl-phenyl)-2,2-dimethyl-cyclopropyl]-2,4- dimethoxy-benzamide;
N-[7>α/?5-2,2-Dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2,4,5-trimethoxy- benzamide; or
N-[7>α/?5-2,2-Dimethyl-3-(4-sulfamoyl-phenyl)-cyclopropyl]-2-methoxy-nicotinamide.
11. A method for preparing a compound of formula r
Figure imgf000078_0001
wherein:
Ar1 and Ar2 each independently is: optionally substituted aryl; or optionally substituted heteroaryl; and R1 and R2 each independently is: hydrogen; fluoro; Ci-βalkyl; or halo-Ci_6alkyl; said method comprising: reacting a cinnamate compound of formula s
Figure imgf000078_0002
wherein R is alkyl, with a Wittig reagent of formula t
Figure imgf000078_0003
to form a cyclopropylester compound of formula u
Figure imgf000078_0004
hydro lyzing said cyclopropyl ester compound of formula u to afford a cyclopropyl acid compound of formula p
Figure imgf000078_0005
treating said cyclopropyl acid compound of formula p with chloro formate ester, followed by sodium azide and acidification, to afford a cyclopropyl amine compound of formula g
Figure imgf000079_0001
reacting said cyclopropyl amine compound of formula g with an acyl reagent of formula j
Ar1-^
X i wherein X is hydroxy, halo or alkoxy, to form said compound of formula r.
12. A pharmaceutical composition comprising a compound of any one of claims 1 to 11 and a pharmaceutically acceptable carrier.
13. The compound of any one of claims 1 to 10, for the treatment of diseases related to the alpha 7 nAHhR receptor.
14. The compound according to claim 13, for the use as cognitive enhancer or for the treatment of Alzheimer's disease.
15. The use of a compound of formula I according to any one of claims 1 to 10 for the preparation of a medicament useful as cognitive enhancer or for the preparation of a medicament for the treatment of Alzheimer's disease.
16. The invention as hereinbefore described.
PCT/EP2008/062813 2007-10-04 2008-09-25 Cyclopropyl aryl amide derivatives and uses thereof WO2009043784A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020107007299A KR101178674B1 (en) 2007-10-04 2008-09-25 Cyclopropyl aryl amide derivatives and uses thereof
JP2010527409A JP5362729B2 (en) 2007-10-04 2008-09-25 Cyclopropylarylamide derivatives and uses thereof
CN2008801100940A CN101815512B (en) 2007-10-04 2008-09-25 Cyclopropyl aryl amide derivatives and uses thereof
ES08804712.1T ES2460897T3 (en) 2007-10-04 2008-09-25 Cyclopropyl aryl amide derivatives and uses thereof
EP08804712.1A EP2207540B1 (en) 2007-10-04 2008-09-25 Cyclopropyl aryl amide derivatives and uses thereof
MX2010003155A MX2010003155A (en) 2007-10-04 2008-09-25 Cyclopropyl aryl amide derivatives and uses thereof.
CA2699625A CA2699625C (en) 2007-10-04 2008-09-25 Cyclopropyl aryl amide derivatives and uses thereof
AU2008307195A AU2008307195B2 (en) 2007-10-04 2008-09-25 Cyclopropyl aryl amide derivatives and uses thereof
IL204437A IL204437A (en) 2007-10-04 2010-03-11 Cyclopropyl aryl amide derivatives and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99758107P 2007-10-04 2007-10-04
US60/997,581 2007-10-04

Publications (1)

Publication Number Publication Date
WO2009043784A1 true WO2009043784A1 (en) 2009-04-09

Family

ID=40130956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/062813 WO2009043784A1 (en) 2007-10-04 2008-09-25 Cyclopropyl aryl amide derivatives and uses thereof

Country Status (11)

Country Link
US (1) US7723391B2 (en)
EP (1) EP2207540B1 (en)
JP (1) JP5362729B2 (en)
KR (1) KR101178674B1 (en)
CN (1) CN101815512B (en)
AU (1) AU2008307195B2 (en)
CA (1) CA2699625C (en)
ES (1) ES2460897T3 (en)
IL (1) IL204437A (en)
MX (1) MX2010003155A (en)
WO (1) WO2009043784A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104782A1 (en) 2011-02-03 2012-08-09 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
WO2012114285A1 (en) 2011-02-23 2012-08-30 Lupin Limited Heteroaryl derivatives as alpha7 nachr modulators
WO2012131576A1 (en) 2011-03-31 2012-10-04 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
WO2013005153A1 (en) 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
WO2013007621A1 (en) 2011-07-08 2013-01-17 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
EP2644595A1 (en) 2012-03-26 2013-10-02 Syngenta Participations AG. N-Cyclylamides as nematicides
US8598213B2 (en) 2011-07-08 2013-12-03 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
WO2014006117A1 (en) 2012-07-06 2014-01-09 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
WO2014019023A1 (en) 2012-08-01 2014-02-06 Bionomics Limited α7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I
WO2014072957A1 (en) 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
WO2014111839A1 (en) 2013-01-16 2014-07-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
WO2014131572A1 (en) 2013-02-27 2014-09-04 Syngenta Participations Ag Novel carboxamide compounds
WO2014141091A1 (en) 2013-03-13 2014-09-18 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
WO2014195848A1 (en) 2013-06-03 2014-12-11 Lupin Limited 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
WO2014203150A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
WO2015003951A1 (en) 2013-07-08 2015-01-15 Syngenta Participations Ag 4-membered ring carboxamides used as nematicides
WO2015040141A1 (en) 2013-09-23 2015-03-26 Syngenta Participations Ag Cyclobutylcarboxamides as nematicides
US9388196B2 (en) 2012-03-06 2016-07-12 Lupin Limited Thiazole derivatives as alpha 7 nAChR modulators
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
WO2018085170A1 (en) * 2016-11-01 2018-05-11 Merck Sharp & Dohme Corp. Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018085171A1 (en) * 2016-11-01 2018-05-11 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018114657A1 (en) 2016-12-20 2018-06-28 Syngenta Participations Ag N-cyclobutyl-thiazol-5-carboxamides with nematicidal activity
US10343985B2 (en) 2013-05-21 2019-07-09 Virginia Commonwealth University Cryopyrin inhibitors for preventing and treating inflammation
WO2020012422A1 (en) 2018-07-13 2020-01-16 Richter Gedeon Nyrt. Spirochromane derivatives
WO2020012423A1 (en) 2018-07-13 2020-01-16 Richter Gedeon Nyrt. Thiadiazine derivatives
WO2020012424A1 (en) 2018-07-13 2020-01-16 Richter Gedeon Nyrt. Substituted (aza)indole derivatives
US10537539B2 (en) 2009-09-22 2020-01-21 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
US11332463B2 (en) 2018-05-01 2022-05-17 Merck Sharp & Dohme Corp. Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024823A2 (en) 2007-08-22 2009-02-26 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
JP5746718B2 (en) * 2010-02-18 2015-07-08 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Solid form consisting of cyclopropylamide derivatives
EP2536702A4 (en) * 2010-02-18 2013-07-10 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative
BR112014019622B8 (en) * 2012-02-14 2020-05-26 Syngenta Participations Ag compound, its uses, pesticidal composition, treated plant propagation material and pharmaceutical compositions
HUE052099T2 (en) 2014-04-04 2021-04-28 Iomet Pharma Ltd Indole derivatives for use in medicine
CN104030930B (en) * 2014-06-20 2016-02-24 河北序能生物技术有限公司 A kind of trans-(1R, 2S)-2-(3,4-difluorophenyl) synthetic method of cyclopropylamine hydrochloride
US10858319B2 (en) 2016-10-03 2020-12-08 Iomet Pharma Ltd. Indole derivatives for use in medicine
CN108586221B (en) * 2018-06-26 2021-03-02 常州制药厂有限公司 Intermediate for preparing ticagrelor and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3192229A (en) * 1962-07-03 1965-06-29 Colgate Palmolive Co Phenylcyclopropyl amides
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
WO2007039173A1 (en) * 2005-10-06 2007-04-12 Sanofi-Aventis Cyclic n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
US20070167497A1 (en) * 2005-09-23 2007-07-19 Pfizer Inc Therapeutic Compounds
WO2007134799A1 (en) * 2006-05-18 2007-11-29 Syngenta Participations Ag Novel microbiocides

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694016A (en) * 1985-10-18 1987-09-15 International Minerals & Chemical Corp. Phthalamide derivatives with anthelmintic activity
IL84944A (en) 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
PL190685B1 (en) 1997-07-25 2005-12-30 Altana Pharma Ag Novel derivatives of tetrazole
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
WO1999027783A1 (en) 1997-12-04 1999-06-10 Dow Agrosciences Llc Fungicidal compositions and methods, and compounds and methods for the preparation thereof
CA2359449A1 (en) 1999-01-15 2000-07-20 Beate Gutterer Phenanthridine-n-oxides with pde-iv inhibiting activity
DE60020079T2 (en) 1999-01-15 2006-01-19 Altana Pharma Ag Phenanthridine N-oxides with PDE-IV inhibitory activity
ATE356810T1 (en) 1999-01-15 2007-04-15 Altana Pharma Ag POLYSUBSTITUTED 6-PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING EFFECT
SI1147089T1 (en) 1999-01-15 2006-04-30 Altana Pharma Ag Phenylphenanthridines with pde-iv inhibiting activity
US20030191279A1 (en) * 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
ATE297905T1 (en) 1999-09-30 2005-07-15 Pfizer Prod Inc 6-AZAURACIL DERIVATIVES AS LIGANDS OF THYROID RECEPTORS
SE9904652D0 (en) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
DE60133879D1 (en) 2000-01-11 2008-06-19 Nycomed Gmbh PHENANTHRIDINE N-OXIDE
WO2002006238A1 (en) 2000-07-14 2002-01-24 Altana Pharma Ag Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
WO2002006239A1 (en) 2000-07-14 2002-01-24 Altana Pharma Ag Phenanthridine n-oxides
AU2001281965A1 (en) 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Novel 6-phenylphenanthridines
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
ES2291455T3 (en) 2001-03-12 2008-03-01 Avanir Pharmaceuticals BENCIMIDAZOL COMPOUNDS TO MODULATE IGE AND INHIBIT THE CELL PROLIFERATION.
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
CA2493816A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
PL374014A1 (en) 2002-08-17 2005-09-19 Altana Pharma Ag Novel phenanthridines having pde 3/4 inhibiting properties
WO2004019944A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
EP2284172A1 (en) 2003-03-14 2011-02-16 MediGene Ltd. Immunomodulating heterocyclic compounds
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
JP2007500686A (en) 2003-07-31 2007-01-18 アルタナ　ファルマ　アクチエンゲゼルシャフト Novel 6-phenylphenanthridine
EP1658270A1 (en) 2003-07-31 2006-05-24 ALTANA Pharma AG Novel 6-phenylphenantridines
EP1720835B1 (en) 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
AR049419A1 (en) 2004-03-03 2006-08-02 Altana Pharma Ag HYDROXI-6-PHENYLPHENANTRIDINES REPLACED WITH HETEROCICLYL
AU2005221831A1 (en) 2004-03-10 2005-09-22 Nycomed Gmbh Novel thio-containing hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
US20070259909A1 (en) 2004-03-10 2007-11-08 Altana Pharma Ag Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors
AU2005221832A1 (en) 2004-03-10 2005-09-22 Nycomed Gmbh Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3192229A (en) * 1962-07-03 1965-06-29 Colgate Palmolive Co Phenylcyclopropyl amides
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
US20070167497A1 (en) * 2005-09-23 2007-07-19 Pfizer Inc Therapeutic Compounds
WO2007039173A1 (en) * 2005-10-06 2007-04-12 Sanofi-Aventis Cyclic n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
WO2007134799A1 (en) * 2006-05-18 2007-11-29 Syngenta Participations Ag Novel microbiocides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURGER A ET AL: "Arylcycloalkylamines. I. 2-Phenylcyclopropylamine", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC.; US, US, vol. 70, 1 January 1948 (1948-01-01), pages 2198 - 2201, XP002489138, ISSN: 0002-7863 *
FILLER R AND WHITE W: "New Reactions of polyfluoroaromatic compounds. II. Polyfluoroaralkyl amines", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY, CHEMICAL SOCIETY. LETCHWORTH, GB, 1 January 1971 (1971-01-01), pages 2062 - 2068, XP009102773, ISSN: 0022-4952 *
R.S. BROWN, T.G. TRAYLOR: "Substituent Effects on sigma-pi-Conjugation. The Absence of pi-Electron Transmission through Cyclopropane Rings", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 95, 1973, pages 8025 - 8032, XP002509077 *

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537539B2 (en) 2009-09-22 2020-01-21 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
US11096916B2 (en) 2009-09-22 2021-08-24 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2012104782A1 (en) 2011-02-03 2012-08-09 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
US9072731B2 (en) 2011-02-23 2015-07-07 Lupin Limited Heteroaryl derivatives as alpha7 nAChR modulators
US9393247B2 (en) 2011-02-23 2016-07-19 Lupin Limited Heteroaryl derivatives as alpha7 nAChR modulators
WO2012114285A1 (en) 2011-02-23 2012-08-30 Lupin Limited Heteroaryl derivatives as alpha7 nachr modulators
US9187420B2 (en) 2011-03-31 2015-11-17 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
WO2012131576A1 (en) 2011-03-31 2012-10-04 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
WO2013005153A1 (en) 2011-07-05 2013-01-10 Lupin Limited Biaryl derivatives as nachr modulators
US8946432B2 (en) 2011-07-05 2015-02-03 Lupin Limited Biaryl derivatives as nAChR modulators
US8598213B2 (en) 2011-07-08 2013-12-03 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
US9050327B2 (en) 2011-07-08 2015-06-09 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
US8765790B2 (en) 2011-07-08 2014-07-01 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
US9549919B2 (en) 2011-07-08 2017-01-24 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
EA028832B1 (en) * 2011-07-08 2018-01-31 Х. Лундбекк А/С Positive allosteric modulators of nicotinic acetylcholine receptor
EA024180B1 (en) * 2011-07-08 2016-08-31 Х. Лундбекк А/С Positive allosteric modulators of nicotinic acetylcholine receptor
RU2604737C2 (en) * 2011-07-08 2016-12-10 Х. Лундбекк А/С Positive allosteric modulators of nicotinic acetylcholine receptor
EP3372582A1 (en) * 2011-07-08 2018-09-12 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
WO2013007621A1 (en) 2011-07-08 2013-01-17 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
US8815914B2 (en) 2011-07-08 2014-08-26 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
US9889122B2 (en) 2011-07-08 2018-02-13 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
AP3793A (en) * 2011-07-08 2016-08-31 Lundbeck & Co As H Positive allosteric modulators of nicotinic acetylcholine receptor
US9023870B2 (en) 2011-07-08 2015-05-05 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
US9388196B2 (en) 2012-03-06 2016-07-12 Lupin Limited Thiazole derivatives as alpha 7 nAChR modulators
EP2644595A1 (en) 2012-03-26 2013-10-02 Syngenta Participations AG. N-Cyclylamides as nematicides
WO2013143811A1 (en) 2012-03-26 2013-10-03 Syngenta Participations Ag N-cyclylamides as nematicides
WO2014006117A1 (en) 2012-07-06 2014-01-09 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
WO2014006120A1 (en) 2012-07-06 2014-01-09 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
US9790173B2 (en) 2012-08-01 2017-10-17 Merck Sharp & Dohme Corp. Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I
EP2888229A4 (en) * 2012-08-01 2016-03-30 Merck Sharp & Dohme alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I
WO2014019023A1 (en) 2012-08-01 2014-02-06 Bionomics Limited α7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I
WO2014072957A1 (en) 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
WO2014111839A1 (en) 2013-01-16 2014-07-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
US9617211B2 (en) 2013-01-16 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
WO2014131572A1 (en) 2013-02-27 2014-09-04 Syngenta Participations Ag Novel carboxamide compounds
US9617210B2 (en) 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
WO2014141091A1 (en) 2013-03-13 2014-09-18 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
US10343985B2 (en) 2013-05-21 2019-07-09 Virginia Commonwealth University Cryopyrin inhibitors for preventing and treating inflammation
US9447037B2 (en) 2013-06-03 2016-09-20 Lupin Limited 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yl)benzenesulfonamide as alpha 7 nAChR modulator
WO2014195848A1 (en) 2013-06-03 2014-12-11 Lupin Limited 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
WO2014203150A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
US9504680B2 (en) 2013-06-17 2016-11-29 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
WO2015003951A1 (en) 2013-07-08 2015-01-15 Syngenta Participations Ag 4-membered ring carboxamides used as nematicides
WO2015040141A1 (en) 2013-09-23 2015-03-26 Syngenta Participations Ag Cyclobutylcarboxamides as nematicides
US9840481B2 (en) 2016-03-22 2017-12-12 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
US9926285B2 (en) 2016-03-22 2018-03-27 Merck Sharp & Dohme Corp. Allosteric modulators of nicotinic acetylcholine receptors
WO2018085171A1 (en) * 2016-11-01 2018-05-11 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
US10870630B2 (en) 2016-11-01 2020-12-22 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
US11026958B2 (en) 2016-11-01 2021-06-08 Merck Sharp & Dohme Corp. Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018085170A1 (en) * 2016-11-01 2018-05-11 Merck Sharp & Dohme Corp. Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
US11793821B2 (en) 2016-11-01 2023-10-24 Merck Sharp & Dohme Llc Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018114657A1 (en) 2016-12-20 2018-06-28 Syngenta Participations Ag N-cyclobutyl-thiazol-5-carboxamides with nematicidal activity
US11332463B2 (en) 2018-05-01 2022-05-17 Merck Sharp & Dohme Corp. Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
WO2020012422A1 (en) 2018-07-13 2020-01-16 Richter Gedeon Nyrt. Spirochromane derivatives
WO2020012423A1 (en) 2018-07-13 2020-01-16 Richter Gedeon Nyrt. Thiadiazine derivatives
WO2020012424A1 (en) 2018-07-13 2020-01-16 Richter Gedeon Nyrt. Substituted (aza)indole derivatives

Also Published As

Publication number Publication date
US20090093525A1 (en) 2009-04-09
IL204437A (en) 2013-09-30
CN101815512A (en) 2010-08-25
ES2460897T3 (en) 2014-05-14
AU2008307195A1 (en) 2009-04-09
AU2008307195B2 (en) 2012-11-22
EP2207540A1 (en) 2010-07-21
MX2010003155A (en) 2010-04-01
US7723391B2 (en) 2010-05-25
CA2699625C (en) 2016-02-02
JP2010540586A (en) 2010-12-24
CN101815512B (en) 2013-04-24
EP2207540B1 (en) 2014-02-26
JP5362729B2 (en) 2013-12-11
CA2699625A1 (en) 2009-04-09
KR20100053677A (en) 2010-05-20
KR101178674B1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
EP2207540B1 (en) Cyclopropyl aryl amide derivatives and uses thereof
US7981914B2 (en) Tetrazole-substituted aryl amide derivatives and uses thereof
US8889665B2 (en) Chemical compounds
JP2002542229A (en) Carbamate derivatives and their use as metabotropic glutamate receptor ligands
OA11663A (en) Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors recptors (antipsychotic agents).
CA2770932A1 (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
CA2728451C (en) Salicylamide derivatives as nicotinic alpha 7 modulators
AU2008307191B2 (en) Tetrazole-substituted aryl amide derivatives and uses thereof
CA2776724A1 (en) Diphenyl azepine derivatives as monoamine reuptake inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880110094.0

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08804712

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008804712

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 204437

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2699625

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008307195

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/003155

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1807/CHENP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107007299

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010527409

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008307195

Country of ref document: AU

Date of ref document: 20080925

Kind code of ref document: A

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0818180

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL, TENDO EM VISTA A NAO ACEITACAO DA ENTRADA NA FASE NACIONAL FACE A INTEMPESTIVIDADE, POIS O PRAZO PARA A REFERIDA ENTRADA EXPIRAVA EM 05/04/2010 (30 MESES CONTADOS DA DATA DE PRIORIDADE) E A ENTRADA SO OCORREU EM 06/04/2010. TAL RETIRADA SE BASEIA NO DISPOSTO NO ITEM 17 DO ATO NORMATIVO 128/1997 C/C ITEM 4.2.1 DO ATO NORMATIVO 127/97. CUMPRE FRISAR QUE A PETICAO NO 020100032406 FOI ENVIADA POR VIA POSTAL, NA CIDADE DA SEDE DO ORGAO, AS 21:46 HRS DO DIA 05/04/2010 (HORARIO POSTERIOR AO ENCERRAMENTO DAS ATIVIDADES DA RECEPCAO DA SEDE DO INPI), MOTIVO PELO QUAL O SERVICO DE PROTOCOLO DO INPI FEZ CONTAR COMO PROTOCOLO O DIA SEGUINTE (VP06/04/2010), EM OBSERVA